k141_64907_2	SARG|gb|AVI44920.1|ARO:3004470|poxtA	25.0	220	247	542	4.66e-14	70.1
k141_64907_2	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	25.0	220	247	544	4.67e-14	70.1
k141_64907_2	ResF|poxtA-Ef_1_WP094899500.1_1	23.7	241	247	538	3.79e-13	67.4
k141_64907_2	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	23.7	241	247	543	3.80e-13	67.4
k141_64907_2	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	23.7	241	247	543	3.80e-13	67.4
k141_64907_2	SARG|U82085.gene.p01	26.8	194	247	552	1.86e-11	62.4
k141_64907_2	SARG|gi|494215524|ref|WP_007131565.1|	27.2	173	247	492	1.42e-10	59.7
k141_64907_2	SARG|gi|738205817|ref|WP_036161732.1|	26.7	191	247	492	4.64e-10	58.2
k141_64907_2	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.0	180	247	655	5.16e-10	58.2
k141_64907_2	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.0	180	247	655	5.16e-10	58.2
k141_39295_5	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.8	286	493	370	1.43e-24	103
k141_39295_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	43.6	225	230	228	4.31e-59	185
k141_39295_6	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.4	229	230	233	1.00e-58	184
k141_39295_6	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.0	230	230	231	3.80e-58	182
k141_39295_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.8	229	230	232	5.54e-58	182
k141_39295_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.4	229	230	232	1.57e-57	181
k141_39295_6	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.6	230	230	231	4.32e-57	180
k141_39295_6	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.6	230	230	231	6.12e-57	179
k141_39295_6	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.9	222	230	219	8.52e-57	179
k141_39295_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.9	227	230	232	8.92e-57	179
k141_39295_6	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	42.6	230	230	231	1.23e-56	179
k141_6860_4	SARG|gi|1016275448|gb|AMX06027.1|	39.4	160	155	646	2.12e-24	97.1
k141_6860_4	SARG|gi|779956086|ref|WP_045403603.1|	39.4	160	155	646	2.89e-24	96.7
k141_6860_4	SARG|gi|695731723|ref|WP_032658224.1|	39.4	160	155	646	2.89e-24	96.7
k141_6860_4	SARG|gi|1016942913|ref|WP_063144441.1|	39.4	160	155	646	2.89e-24	96.7
k141_6860_4	SARG|gi|981224618|ref|WP_059445588.1|	39.4	160	155	646	2.89e-24	96.7
k141_6860_4	SARG|gi|1028212610|ref|WP_063955653.1|	39.4	160	155	646	2.89e-24	96.7
k141_6860_4	SARG|gi|835749851|ref|WP_047648187.1|	39.4	160	155	646	2.89e-24	96.7
k141_6860_4	SARG|gi|697052471|ref|WP_033145077.1|	39.4	160	155	646	2.89e-24	96.7
k141_6860_4	SARG|gi|695722592|ref|WP_032649220.1|	39.4	160	155	646	2.89e-24	96.7
k141_6860_4	SARG|gi|895868403|ref|WP_048976842.1|	39.4	160	155	646	2.89e-24	96.7
k141_44427_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.8	177	191	1197	6.36e-25	100
k141_44427_1	CARD|gb|ADM92605.1|ARO:3000553|adeR	36.1	119	191	247	2.87e-13	65.1
k141_44427_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.8	107	191	231	1.06e-10	57.8
k141_44427_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.0	107	191	232	2.24e-08	51.2
k141_39318_7	ResF|poxtA-Ef_1_WP094899500.1_1	27.5	222	264	538	1.66e-12	65.9
k141_39318_7	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	27.5	222	264	543	1.67e-12	65.9
k141_39318_7	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	27.5	222	264	543	1.67e-12	65.9
k141_39318_7	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.8	176	264	664	1.07e-11	63.5
k141_39318_7	SARG|gb|WP_082039181.1|ARO:3007028|salD	28.4	169	264	544	3.24e-11	62.0
k141_39318_7	SARG|gb|CDO61516.1|ARO:3003949|efrB	23.9	188	264	362	1.09e-10	60.1
k141_39318_7	SARG|U82085.gene.p01	29.4	187	264	552	2.57e-10	59.3
k141_39318_7	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.2	202	264	655	2.74e-10	59.3
k141_39318_7	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.2	202	264	655	2.74e-10	59.3
k141_39318_7	SARG|gb|AVI44920.1|ARO:3004470|poxtA	27.6	181	264	542	6.16e-10	58.2
k141_46210_3	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	45.7	1012	1040	1033	0.0	939
k141_46210_3	SARG|gb|AEY83581|ARO:3000510|mupB	45.7	1012	1040	1033	0.0	939
k141_46210_3	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	44.5	1035	1040	1024	0.0	936
k141_46210_3	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.5	1035	1040	1024	0.0	936
k141_46210_3	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.3	1035	1040	1024	0.0	928
k141_46210_3	SARG|gb|CAA53189|ARO:3000521|mupA	44.3	1035	1040	1024	0.0	928
k141_46210_3	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	37.3	1066	1040	1107	8.95e-228	677
k141_46210_3	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	37.3	1066	1040	1107	8.95e-228	677
k141_30783_5	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	31.4	334	489	593	1.57e-25	108
k141_30783_5	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	24.8	443	489	674	6.19e-21	95.1
k141_30783_5	SARG|gb|BAI83385.1|ARO:3003440|mecB	26.1	448	489	674	8.24e-21	94.7
k141_30783_5	ResF|penA_1_AF515059_1	24.2	414	489	581	4.30e-14	73.6
k141_15460_4	SARG|gb|AAK76136.1|ARO:3000025|patB	28.2	216	251	588	1.16e-14	72.0
k141_15460_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.5	244	251	664	4.03e-14	70.5
k141_15460_4	SARG|gi|748767925|ref|WP_040019608.1|	27.0	230	251	623	1.42e-12	65.9
k141_15460_4	SARG|gi|662754041|ref|WP_030125200.1|	27.4	248	251	601	3.43e-12	64.7
k141_15460_4	SARG|gi|664100597|ref|WP_030638327.1|	27.4	248	251	601	3.43e-12	64.7
k141_15460_4	SARG|gi|505389066|ref|WP_015576168.1|	27.4	248	251	601	3.43e-12	64.7
k141_15460_4	SARG|gi|503923650|ref|WP_014157644.1|	27.4	248	251	601	3.43e-12	64.7
k141_15460_4	SARG|AF170880.4.gene1.p01	27.3	242	251	615	3.46e-12	64.7
k141_15460_4	SARG|gi|558888514|ref|WP_023543283.1|	27.3	242	251	615	3.46e-12	64.7
k141_15460_4	SARG|gi|926400371|ref|WP_053728483.1|	27.9	233	251	603	6.24e-12	63.9
k141_76979_2	SARG|YP_302230	22.9	280	456	451	4.70e-13	69.7
k141_37729_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	46.5	230	235	228	2.02e-66	204
k141_37729_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.4	226	235	231	1.40e-59	186
k141_37729_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.5	226	235	232	8.19e-59	184
k141_37729_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.5	224	235	219	1.56e-58	183
k141_37729_2	CARD|gb|AAG05188.1|ARO:3005068|ParR	40.5	227	235	235	1.32e-55	176
k141_37729_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	40.5	232	235	229	6.23e-55	174
k141_37729_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.1	232	235	235	5.97e-54	172
k141_37729_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.6	234	235	232	7.73e-54	172
k141_37729_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.6	234	235	232	7.73e-54	172
k141_37729_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.5	231	235	232	1.55e-53	171
k141_37729_3	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.1	270	473	467	9.51e-30	120
k141_37729_3	CARD|gb|CYF42523.1|ARO:3004047|kdpD	27.0	222	473	885	6.20e-18	85.9
k141_37729_7	megares|MEG_7543|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	33.8	130	518	281	6.15e-14	71.2
k141_37729_7	megares|MEG_7544|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	33.8	130	518	281	6.15e-14	71.2
k141_37729_7	NCBI|WP_063856762.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	33.8	130	518	281	6.15e-14	71.2
k141_37729_7	NCBI|WP_021419095.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	33.8	130	518	281	6.15e-14	71.2
k141_53112_5	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	40.4	104	181	159	2.38e-11	58.2
k141_53112_5	SARG|gi|515720450|ref|WP_017153050.1|	33.7	92	181	210	6.57e-10	55.1
k141_53112_5	SARG|AF155139.2.gene5.p01	41.3	63	181	206	1.19e-09	54.3
k141_53112_5	SARG|gi|1028848471|ref|WP_064017434.1|	42.9	63	181	206	1.19e-09	54.3
k141_53112_5	SARG|gi|670466162|ref|WP_031414939.1|	42.9	63	181	206	1.64e-09	53.9
k141_37751_2	SARG|gb|CAE00499.1|ARO:3003835|cdeA	26.4	425	458	441	2.77e-48	170
k141_37751_2	SARG|gi|505177635|ref|WP_015364737.1|	25.6	433	458	451	9.35e-37	139
k141_195_3	NCBI|CAJ68095.1|1|1|vanZ1|vanZ1|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ1|AMR|glycopeptide	43.9	155	173	169	4.14e-36	122
k141_195_3	SARG|CAB61225	39.2	148	173	161	1.69e-24	92.4
k141_195_3	SARG|ACP19239	37.2	148	173	161	6.69e-24	90.9
k141_195_3	megares|MEG_7452|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.2	148	173	161	6.69e-24	90.9
k141_195_3	SARG|AF155139.2.gene5.p01	30.7	114	173	206	9.54e-09	51.6
k141_195_3	SARG|gi|670466162|ref|WP_031414939.1|	32.0	100	173	206	5.78e-07	46.6
k141_195_3	SARG|gi|515720450|ref|WP_017153050.1|	32.4	105	173	210	5.95e-07	46.6
k141_195_3	SARG|gi|1028848471|ref|WP_064017434.1|	32.0	100	173	206	1.48e-06	45.4
k141_20651_5	CARD|gb|AFK13828.1|ARO:3000823|ramA	32.0	103	314	124	1.26e-11	60.1
k141_20651_8	SARG|gb|AYV52072.1|ARO:3002882|lmrD	69.2	52	60	664	2.01e-20	81.3
k141_20651_8	SARG|gb|AAK76136.1|ARO:3000025|patB	69.2	52	60	588	3.75e-20	80.5
k141_20651_8	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	58.3	48	60	578	1.85e-14	64.3
k141_20651_8	SARG|gi|948137056|ref|WP_056795395.1|	58.3	48	60	602	3.09e-13	60.8
k141_20651_8	SARG|gi|817122037|ref|WP_046494699.1|	56.3	48	60	613	5.77e-13	60.1
k141_20651_8	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	40.4	52	60	574	5.65e-10	51.6
k141_20651_9	SARG|gi|447195835|ref|WP_001273091.1|	42.5	212	212	306	8.71e-49	160
k141_20651_9	SARG|ZP_04081918	42.0	212	212	306	1.73e-48	159
k141_20651_9	SARG|gi|447195836|ref|WP_001273092.1|	42.0	212	212	306	2.45e-48	159
k141_20651_9	SARG|gi|507044560|ref|WP_016115614.1|	42.0	212	212	306	3.45e-48	159
k141_20651_9	SARG|gi|445996719|ref|WP_000074574.1|	41.3	208	212	309	1.04e-47	157
k141_20651_9	SARG|YP_001373621	41.8	208	212	318	1.31e-47	157
k141_20651_9	SARG|gi|500194536|ref|WP_011867743.1|	42.5	212	212	306	2.71e-47	156
k141_20651_9	SARG|gi|500448961|gb|EOP61695.1|	41.5	212	212	306	5.40e-47	155
k141_20651_9	SARG|gi|446026113|ref|WP_000103968.1|	41.5	212	212	306	5.40e-47	155
k141_20651_9	SARG|gi|445996724|ref|WP_000074579.1|	41.3	208	212	309	5.82e-47	155
k141_20651_15	SARG|gb|AAK76136.1|ARO:3000025|patB	34.4	585	618	588	4.68e-108	336
k141_20651_15	SARG|gb|CDO61516.1|ARO:3003949|efrB	50.0	326	618	362	9.19e-105	320
k141_20651_15	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.8	514	618	664	1.67e-99	316
k141_20651_15	SARG|gi|928900436|ref|WP_053931243.1|	33.3	589	618	600	1.87e-88	285
k141_20651_15	SARG|gi|664579989|ref|WP_031094015.1|	33.3	589	618	601	1.92e-88	285
k141_20651_15	SARG|gi|947982677|ref|WP_056642336.1|	32.6	585	618	626	6.92e-88	285
k141_20651_15	SARG|AF170880.4.gene1.p01	33.5	588	618	615	7.44e-88	284
k141_20651_15	SARG|gi|664556405|ref|WP_031071225.1|	33.4	589	618	602	7.58e-88	284
k141_20651_15	SARG|gi|639892676|ref|WP_024755698.1|	32.6	585	618	631	7.80e-88	285
k141_20651_15	SARG|gi|944152509|ref|WP_055644808.1|	32.6	585	618	616	2.09e-87	283
k141_20651_16	SARG|gb|WP_104671188.1|ARO:3003948|efrA	44.4	525	773	575	9.62e-136	412
k141_20651_16	SARG|gb|AAK76137.1|ARO:3000024|patA	38.5	494	773	564	4.31e-110	345
k141_20651_16	SARG|gi|943896259|ref|WP_055534530.1|	36.2	359	773	601	1.20e-64	225
k141_20651_16	SARG|gi|1011969930|ref|WP_062776015.1|	36.1	360	773	601	4.34e-64	224
k141_20651_16	SARG|AF170880.4.gene1.p01	31.4	509	773	615	1.09e-63	223
k141_20651_16	SARG|gi|558888514|ref|WP_023543283.1|	31.2	509	773	615	1.09e-63	223
k141_20651_16	SARG|gi|943909899|ref|WP_055545300.1|	35.9	359	773	601	2.99e-63	221
k141_20651_16	SARG|gi|748767925|ref|WP_040019608.1|	36.2	359	773	623	3.31e-63	222
k141_20651_16	SARG|gi|1045390184|ref|WP_065479071.1|	36.2	359	773	605	4.45e-63	221
k141_20651_16	SARG|gi|928900436|ref|WP_053931243.1|	35.7	359	773	600	5.56e-63	221
k141_73549_2	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.3	251	436	355	1.18e-18	85.9
k141_73549_2	SARG|BAE96115	28.3	251	436	355	1.18e-18	85.9
k141_73549_2	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.6	252	436	356	2.91e-18	84.7
k141_73549_2	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	28.0	186	436	209	5.18e-12	63.9
k141_42833_2	SARG|gb|AAV85982.1|ARO:3000535|macB	35.1	419	417	644	1.45e-48	174
k141_42833_2	SARG|gi|1001720867|ref|WP_061274204.1|	31.3	419	417	648	1.52e-33	131
k141_42833_2	SARG|gi|1035670474|ref|WP_064517458.1|	31.4	424	417	648	2.06e-33	131
k141_42833_2	SARG|gi|1035717981|ref|WP_064557480.1|	31.4	424	417	648	2.06e-33	131
k141_42833_2	SARG|gi|495736522|ref|WP_008461101.1|	31.0	420	417	648	2.80e-33	130
k141_42833_2	SARG|gi|746243059|ref|WP_039291473.1|	31.0	420	417	648	2.80e-33	130
k141_42833_2	SARG|gi|746253210|ref|WP_039301529.1|	31.0	420	417	648	2.80e-33	130
k141_42833_2	SARG|gi|495067432|ref|WP_007792257.1|	29.9	421	417	647	9.42e-33	129
k141_42833_2	SARG|gi|1035706844|ref|WP_064548272.1|	30.5	420	417	648	9.46e-33	129
k141_42833_2	SARG|gi|736472622|ref|WP_034494292.1|	30.9	424	417	648	1.74e-32	128
k141_70130_7	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.3	225	686	359	3.83e-20	91.7
k141_70130_7	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	29.3	222	686	364	1.32e-19	90.1
k141_70130_7	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	29.3	222	686	364	1.32e-19	90.1
k141_70130_7	CARD|gb|AEX49906.1|ARO:3003583|basS	25.1	231	686	477	6.95e-15	76.6
k141_70130_7	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	23.5	260	686	341	1.77e-10	62.0
k141_70130_7	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.6	115	686	219	7.51e-10	58.5
k141_70130_7	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.6	115	686	219	7.51e-10	58.5
k141_70130_7	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.6	115	686	220	7.62e-10	58.5
k141_70130_7	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.6	115	686	220	1.39e-09	57.8
k141_70130_7	CARD|gb|AAG06465.1|ARO:3005063|cprR	31.4	121	686	223	8.66e-09	55.5
k141_70130_14	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.8	630	655	655	7.04e-169	496
k141_70130_14	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.7	630	655	655	5.62e-168	494
k141_70130_14	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.7	630	655	655	1.12e-167	493
k141_70130_14	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	1.59e-167	493
k141_70130_14	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	3.17e-167	492
k141_70130_14	SARG|gb|AKA86814|ARO:3003746|optrA	43.5	630	655	655	3.17e-167	492
k141_70130_14	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	6.34e-167	491
k141_70130_14	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	8.96e-167	491
k141_70130_14	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	8.96e-167	491
k141_70130_14	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	2.53e-166	490
k141_71903_1	SARG|gb|AAK76136.1|ARO:3000025|patB	51.0	245	308	588	6.51e-79	249
k141_71903_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	45.6	305	308	664	6.46e-78	249
k141_71903_1	SARG|gi|748767925|ref|WP_040019608.1|	51.7	240	308	623	1.24e-75	242
k141_71903_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	57.3	199	308	362	7.14e-75	233
k141_71903_1	SARG|gi|663350985|ref|WP_030349761.1|	50.8	240	308	613	1.52e-74	239
k141_71903_1	SARG|gi|926400371|ref|WP_053728483.1|	50.2	249	308	603	1.73e-74	238
k141_71903_1	SARG|gi|695865802|ref|WP_032778631.1|	50.0	240	308	605	4.98e-74	237
k141_71903_1	SARG|gi|663330365|ref|WP_030329892.1|	50.4	240	308	607	5.19e-74	237
k141_71903_1	SARG|gi|944009777|ref|WP_055601444.1|	50.8	242	308	628	5.69e-74	238
k141_71903_1	SARG|gi|662175949|ref|WP_030118884.1|	50.4	240	308	605	6.99e-74	237
k141_54768_2	SARG|gb|AGN74946|ARO:3003749|salA	23.6	518	517	541	6.38e-35	136
k141_54768_2	SARG|gb|ABX00624.1|ARO:3002881|lmrC	26.8	530	517	550	8.11e-34	133
k141_54768_2	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	24.9	502	517	461	4.93e-29	118
k141_54768_2	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	24.5	494	517	461	4.12e-28	115
k141_54768_2	SARG|gb|WP_096809342.1|ARO:3007029|salE	22.9	498	517	543	8.06e-28	115
k141_54768_2	SARG|AY004350.gene.p01	24.1	507	517	492	3.32e-22	98.6
k141_54768_2	SARG|FR772051.1.gene9.p01	36.3	215	517	524	3.89e-22	98.6
k141_54768_2	SARG|gi|488321355|ref|WP_002390740.1|	25.2	512	517	492	4.44e-22	98.2
k141_54768_2	SARG|gi|488243106|ref|WP_002314314.1|	24.2	504	517	492	5.94e-22	97.8
k141_54768_2	SARG|gi|488216250|ref|WP_002287458.1|	24.1	507	517	492	1.42e-21	96.7
k141_78702_17	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.4	665	663	885	2.04e-84	283
k141_78702_17	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.4	229	663	381	1.50e-19	90.1
k141_78702_17	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.4	229	663	381	1.50e-19	90.1
k141_78702_17	SARG|gb|AAG05187.1|ARO:3005067|ParS	28.6	220	663	428	2.29e-19	90.1
k141_78702_17	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.4	229	663	381	2.70e-19	89.4
k141_78702_17	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.4	229	663	381	2.70e-19	89.4
k141_78702_17	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.2	216	663	361	2.92e-19	89.0
k141_78702_17	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	25.0	304	663	367	4.18e-19	88.6
k141_78702_17	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.9	214	663	381	4.84e-19	88.6
k141_78702_17	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.9	214	663	381	4.84e-19	88.6
k141_8743_3	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	24.1	237	470	397	5.19e-10	60.1
k141_12248_7	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	31.3	265	288	357	4.83e-27	107
k141_12248_7	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	31.3	265	288	357	4.83e-27	107
k141_12248_7	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.6	275	288	365	2.17e-22	94.4
k141_12248_7	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.5	241	288	392	1.85e-21	92.0
k141_12248_7	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	31.6	234	288	380	1.83e-19	86.3
k141_12248_7	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.6	234	288	380	1.83e-19	86.3
k141_12248_7	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.7	232	288	352	5.06e-19	84.7
k141_12248_7	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	28.3	251	288	388	6.67e-19	84.7
k141_12248_7	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	251	288	388	6.67e-19	84.7
k141_12248_7	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.9	231	288	376	8.37e-19	84.3
k141_8755_2	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.8	194	348	258	5.58e-20	87.0
k141_8755_2	SARG|gb|AAK76136.1|ARO:3000025|patB	26.3	213	348	588	3.64e-10	60.1
k141_8755_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	23.6	191	348	664	6.43e-08	53.1
k141_8755_2	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	22.1	195	348	578	1.89e-07	51.6
k141_8755_2	SARG|gi|736993687|ref|WP_034989673.1|	63.6	33	348	513	2.28e-06	48.1
k141_8755_2	SARG|AF024666.2.gene6.p01	63.6	33	348	513	2.28e-06	48.1
k141_8755_2	SARG|gi|171851258|emb|CAQ04234.1|	60.6	33	348	483	5.17e-06	47.0
k141_10459_2	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	37.1	283	331	308	5.04e-47	160
k141_10459_2	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	38.5	231	331	310	1.82e-43	150
k141_71992_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	38.8	227	248	255	1.54e-41	141
k141_71992_2	SARG|gi|495736522|ref|WP_008461101.1|	37.2	226	248	648	1.05e-39	144
k141_71992_2	SARG|gi|823326845|ref|WP_047080664.1|	36.3	226	248	648	1.13e-36	135
k141_71992_2	SARG|gi|695793471|ref|WP_032707680.1|	36.3	226	248	648	1.13e-36	135
k141_71992_2	SARG|gi|823302270|ref|WP_047057473.1|	36.3	226	248	648	1.13e-36	135
k141_71992_2	SARG|gi|976146774|ref|WP_059305359.1|	36.3	226	248	648	1.13e-36	135
k141_71992_2	SARG|gi|1022664304|ref|WP_063420886.1|	36.3	226	248	648	1.13e-36	135
k141_71992_2	SARG|gi|895981299|ref|WP_049056431.1|	36.3	226	248	648	1.13e-36	135
k141_71992_2	SARG|gi|823309640|ref|WP_047064288.1|	36.3	226	248	648	1.13e-36	135
k141_71992_2	SARG|gi|823281237|ref|WP_047037467.1|	36.3	226	248	648	1.13e-36	135
k141_8801_3	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	27.2	276	294	346	9.92e-19	84.0
k141_22424_3	NCBI|WP_256875606.1|1|1|blaNWM-1|blaNWM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_NWM-1|AMR|beta-lactam	31.3	80	266	310	1.62e-06	47.4
k141_22424_7	SARG|gi|985522333|ref|WP_060811962.1|	39.1	289	331	323	2.09e-61	197
k141_22424_7	SARG|gi|498515089|ref|WP_010815296.1|	38.8	289	331	323	1.16e-60	196
k141_22424_7	SARG|Q47748	39.1	289	331	323	1.16e-60	196
k141_22424_7	SARG|gb|AAB05626.1|ARO:3002943|vanHB	39.1	289	331	323	1.16e-60	196
k141_22424_7	SARG|YP_002333394	39.1	289	331	323	4.60e-60	194
k141_22424_7	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	39.1	289	331	323	4.60e-60	194
k141_22424_7	SARG|AF310956.2.gene5.p01	39.1	289	331	323	6.48e-60	194
k141_22424_7	SARG|DQ018711.1.gene4.p01	35.0	317	331	322	2.75e-58	189
k141_22424_7	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	40.5	259	331	343	9.61e-58	189
k141_22424_7	SARG|gi|737310392|ref|WP_035293250.1|	35.0	317	331	323	1.57e-57	187
k141_72074_10	SARG|gi|981224618|ref|WP_059445588.1|	32.6	218	296	646	5.14e-28	112
k141_72074_10	SARG|gi|498115003|ref|WP_010429159.1|	32.7	211	296	646	6.98e-28	112
k141_72074_10	SARG|gi|998245120|ref|WP_061098715.1|	32.2	211	296	646	2.37e-27	110
k141_72074_10	SARG|gi|836585048|ref|WP_047742322.1|	32.7	211	296	646	2.37e-27	110
k141_72074_10	SARG|gi|695748190|ref|WP_032674455.1|	32.2	211	296	646	5.91e-27	109
k141_72074_10	SARG|gi|779866095|ref|WP_045354445.1|	32.2	211	296	646	5.91e-27	109
k141_72074_10	SARG|gi|544824889|ref|WP_021240890.1|	32.2	211	296	646	5.91e-27	109
k141_72074_10	SARG|gi|779956086|ref|WP_045403603.1|	32.2	211	296	646	5.91e-27	109
k141_72074_10	SARG|gi|695731723|ref|WP_032658224.1|	32.2	211	296	646	5.91e-27	109
k141_72074_10	SARG|gi|851931792|ref|WP_048222288.1|	32.2	211	296	646	5.91e-27	109
k141_72074_11	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.4	204	295	255	9.43e-27	104
k141_72074_11	SARG|ABB80128	29.3	232	295	306	1.28e-25	102
k141_72074_11	SARG|P42332	28.9	232	295	306	1.26e-24	99.8
k141_72074_11	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.9	232	295	306	1.26e-24	99.8
k141_72074_11	SARG|gi|510143239|gb|AGN36970.1|	28.9	232	295	313	1.40e-24	99.8
k141_72074_11	SARG|AAD21213	28.4	232	295	306	8.83e-24	97.4
k141_72074_11	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	28.1	231	295	579	5.34e-22	94.7
k141_72074_11	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.3	249	295	582	4.43e-21	92.0
k141_72074_11	SARG|gi|953808775|ref|WP_058042812.1|	30.0	247	295	608	1.52e-20	90.5
k141_72074_11	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	25.9	232	295	579	3.63e-20	89.4
k141_3735_5	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.6	224	230	231	1.28e-61	191
k141_3735_5	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.5	229	230	232	5.30e-61	190
k141_3735_5	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.5	229	230	232	5.30e-61	190
k141_3735_5	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.4	225	230	233	3.54e-59	185
k141_3735_5	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	44.0	232	230	239	1.37e-57	181
k141_3735_5	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	44.3	228	230	235	1.72e-57	181
k141_3735_5	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	43.8	226	230	232	2.22e-57	181
k141_3735_5	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	44.7	226	230	232	6.30e-57	179
k141_3735_5	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.6	227	230	232	8.92e-57	179
k141_3735_5	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.9	225	230	229	3.27e-56	177
k141_3735_6	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	31.0	229	505	359	9.95e-25	104
k141_3735_6	SARG|gb|AAG05187.1|ARO:3005067|ParS	26.7	303	505	428	2.64e-22	98.2
k141_3735_6	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.5	314	505	370	3.61e-22	97.1
k141_3735_6	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	24.0	296	505	365	6.80e-21	93.2
k141_3735_6	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.3	245	505	364	3.42e-18	85.1
k141_3735_6	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.3	245	505	364	3.42e-18	85.1
k141_3735_6	CARD|gb|AEX49906.1|ARO:3003583|basS	23.5	294	505	477	9.50e-18	84.7
k141_72135_1	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	25.0	208	221	443	8.43e-14	68.6
k141_72135_1	SARG|BAA31456	27.8	209	221	456	1.08e-11	62.4
k141_70324_5	SARG|gi|851935911|ref|WP_048224705.1|	32.3	322	324	660	6.07e-45	161
k141_70324_5	SARG|gi|1002399350|ref|WP_061382108.1|	32.3	322	324	660	6.07e-45	161
k141_70324_5	SARG|gi|757799830|ref|WP_043017032.1|	32.0	322	324	660	8.36e-45	160
k141_70324_5	SARG|gi|851917461|ref|WP_048217311.1|	31.7	322	324	660	3.01e-44	159
k141_70324_5	SARG|gi|489117806|ref|WP_003027650.1|	31.7	322	324	660	3.01e-44	159
k141_70324_5	SARG|gi|696375142|ref|WP_032949690.1|	31.7	322	324	660	3.01e-44	159
k141_70324_5	SARG|gi|851981245|ref|WP_048240645.1|	31.7	322	324	660	3.01e-44	159
k141_70324_5	SARG|gi|765458296|ref|WP_044714032.1|	31.7	322	324	660	4.15e-44	159
k141_70324_5	SARG|B1LLK9	31.7	322	324	660	1.08e-43	157
k141_70324_5	SARG|gi|507079934|ref|WP_016150692.1|	31.4	322	324	660	2.05e-43	157
k141_73876_4	SARG|gb|BAG33043.1|ARO:3003920|pgpB	28.9	173	174	236	2.31e-08	50.8
k141_73876_4	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	28.9	173	174	236	2.31e-08	50.8
k141_75574_2	SARG|gb|CAE00499.1|ARO:3003835|cdeA	27.9	384	393	441	8.56e-37	137
k141_75574_2	SARG|gi|488374619|ref|WP_002444004.1|	27.0	345	393	452	3.71e-28	114
k141_66814_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	30.5	105	227	235	4.52e-09	53.9
k141_66814_2	SARG|ZP_02848503	36.3	80	227	221	7.43e-09	53.1
k141_66814_2	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.5	92	227	232	2.06e-08	52.0
k141_66814_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.5	92	227	232	2.79e-08	51.6
k141_66814_2	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.5	92	227	232	2.79e-08	51.6
k141_66814_2	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.5	92	227	232	2.79e-08	51.6
k141_66814_2	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.5	92	227	232	2.79e-08	51.6
k141_66814_2	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.5	92	227	232	2.79e-08	51.6
k141_66814_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	66	227	220	7.33e-07	47.4
k141_66814_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	26.2	107	227	231	1.07e-06	47.0
k141_53509_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	47.3	186	188	228	3.46e-52	166
k141_53509_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	45.0	189	188	232	4.04e-49	158
k141_53509_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.8	185	188	231	2.52e-47	153
k141_53509_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.1	183	188	219	4.07e-46	150
k141_53509_3	CARD|gb|AAG05188.1|ARO:3005068|ParR	38.6	184	188	235	1.62e-43	144
k141_53509_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.3	183	188	232	4.23e-43	142
k141_53509_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.3	183	188	232	4.23e-43	142
k141_53509_3	CARD|gb|AAD51348.1|ARO:3003066|smeR	42.4	184	188	229	1.55e-42	141
k141_53509_3	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.2	186	188	232	6.72e-42	139
k141_53509_3	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.2	186	188	232	9.50e-42	139
k141_79105_4	SARG|DQ018711.1.gene4.p01	31.3	262	319	322	2.88e-28	110
k141_79105_4	SARG|gi|737310392|ref|WP_035293250.1|	31.3	262	319	323	1.50e-27	108
k141_79105_4	SARG|AF155139.2.gene6.p01	35.4	237	319	322	3.93e-27	107
k141_79105_4	SARG|gi|746609237|ref|WP_039635344.1|	32.7	257	319	322	1.04e-26	106
k141_36377_6	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	25.1	509	466	533	1.38e-32	129
k141_682_3	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.0	432	605	629	1.32e-24	107
k141_682_3	ResF|tet(O/W)_3_AM889120_1	28.0	432	605	639	1.36e-24	107
k141_682_3	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.0	432	605	629	3.09e-24	106
k141_682_3	ResF|tet(O/W)_4_AM889121_1	28.0	432	605	639	3.18e-24	106
k141_682_3	SARG|CAE46078	26.5	438	605	639	4.23e-24	105
k141_682_3	SARG|gi|1004359922|gb|AMP42228.1|	27.1	431	605	639	9.90e-24	104
k141_682_3	SARG|P21598	26.3	438	605	639	9.90e-24	104
k141_682_3	SARG|ABN79417	27.5	432	605	639	9.90e-24	104
k141_682_3	SARG|gi|291587251|gb|ADE19326.1|	26.3	438	605	644	1.00e-23	104
k141_682_3	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.9	437	605	629	1.28e-23	104
k141_682_5	SARG|gi|1035706844|ref|WP_064548272.1|	37.7	77	966	648	1.11e-07	54.7
k141_38018_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.5	123	671	231	7.41e-08	52.8
k141_38018_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.5	114	671	232	7.49e-08	52.8
k141_743_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	44.1	681	644	703	2.14e-174	512
k141_38136_2	SARG|gi|695273519|ref|WP_032495453.1|	31.6	187	291	245	1.37e-20	87.4
k141_38136_2	NCBI|WP_063844619.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.0	187	291	245	1.37e-20	87.4
k141_38136_2	SARG|gi|488250641|ref|WP_002321849.1|	31.6	187	291	245	1.90e-20	87.0
k141_38136_2	NCBI|WP_063844598.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.6	187	291	245	2.63e-20	86.7
k141_38136_2	megares|MEG_2801|Drugs|MLS|23S_rRNA_methyltransferases|ERMB_1	31.6	187	291	253	3.02e-20	86.7
k141_38136_2	NCBI|WP_001038790.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.6	187	291	245	3.64e-20	86.3
k141_38136_2	NCBI|WP_063844601.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.0	187	291	245	6.96e-20	85.5
k141_38136_2	SARG|AAL91930	31.0	187	291	245	9.62e-20	85.1
k141_38136_2	SARG|gi|494752321|ref|WP_007487729.1|	31.4	188	291	245	9.62e-20	85.1
k141_38136_2	NCBI|WP_063844614.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.0	187	291	245	9.62e-20	85.1
k141_43441_2	CARD|gb|ABD30512.1|ARO:3000839|arlS	32.5	252	553	451	1.66e-27	114
k141_43441_2	CARD|gb|AEX49906.1|ARO:3003583|basS	33.8	219	553	477	4.86e-23	101
k141_43441_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.7	223	224	219	5.28e-51	164
k141_43441_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.4	224	224	228	9.73e-51	163
k141_43441_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.5	220	224	219	3.06e-47	154
k141_43441_3	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.5	220	224	220	3.15e-47	154
k141_43441_3	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.5	220	224	220	4.45e-47	154
k141_43441_3	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.0	220	224	220	6.30e-47	153
k141_43441_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.1	220	224	219	2.44e-46	152
k141_43441_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.0	230	224	232	3.97e-45	149
k141_43441_3	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.3	229	224	231	5.45e-45	149
k141_43441_3	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.3	229	224	231	5.45e-45	149
k141_50038_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.1	553	587	575	4.73e-109	337
k141_50038_4	SARG|gb|AAK76137.1|ARO:3000024|patA	33.5	568	587	564	1.29e-88	284
k141_50038_4	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.0	467	587	579	1.77e-61	212
k141_50038_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	26.5	563	587	582	6.94e-61	211
k141_50038_4	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.0	467	587	579	1.25e-59	207
k141_50038_4	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.4	583	587	579	4.51e-58	203
k141_50038_4	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.8	583	587	579	3.18e-57	201
k141_50038_4	SARG|gi|505420018|ref|WP_015607120.1|	29.8	476	587	603	4.30e-54	192
k141_50038_4	SARG|gi|695842130|ref|WP_032755430.1|	29.8	476	587	603	5.93e-54	192
k141_50038_4	SARG|gi|648667297|ref|WP_026359044.1|	28.6	538	587	605	1.61e-53	191
k141_50038_5	SARG|gb|AAK76136.1|ARO:3000025|patB	35.7	572	585	588	5.49e-99	311
k141_50038_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.1	507	585	664	8.66e-96	305
k141_50038_5	SARG|gb|CDO61516.1|ARO:3003949|efrB	43.5	333	585	362	9.38e-85	267
k141_50038_5	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.3	577	585	579	5.61e-80	261
k141_50038_5	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.4	575	585	579	3.15e-78	257
k141_50038_5	SARG|gi|928900436|ref|WP_053931243.1|	32.3	514	585	600	1.08e-75	251
k141_50038_5	SARG|gi|664579989|ref|WP_031094015.1|	32.3	514	585	601	1.10e-75	251
k141_50038_5	SARG|gi|860594225|ref|WP_048475168.1|	29.9	579	585	620	1.73e-74	248
k141_50038_5	SARG|gi|517347347|ref|WP_018522839.1|	33.3	498	585	601	4.34e-74	246
k141_50038_5	SARG|gi|926376632|ref|WP_053705806.1|	33.3	511	585	620	4.68e-74	247
k141_61889_2	SARG|gb|APB03219.1|ARO:3003986|TaeA	49.2	433	438	648	1.99e-136	405
k141_61889_2	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	313	438	655	1.28e-35	138
k141_61889_2	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	313	438	655	1.28e-35	138
k141_61889_2	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	313	438	655	4.34e-35	136
k141_61889_2	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	313	438	655	4.34e-35	136
k141_61889_2	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	313	438	655	4.34e-35	136
k141_61889_2	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	313	438	655	4.34e-35	136
k141_61889_2	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	313	438	655	4.34e-35	136
k141_61889_2	SARG|gb|AKA86814|ARO:3003746|optrA	31.0	313	438	655	4.34e-35	136
k141_61889_2	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	30.1	336	438	487	4.95e-35	134
k141_17823_8	SARG|gi|542061059|gb|ERI11611.1|	27.0	244	279	316	8.38e-20	86.3
k141_17823_8	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	24.6	248	279	293	1.15e-15	74.3
k141_17823_8	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.5	245	279	664	3.37e-15	74.3
k141_17823_8	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	22.9	249	279	307	6.24e-15	72.4
k141_17823_8	SARG|gi|1032346815|ref|WP_064200323.1|	46.2	52	279	492	2.40e-07	50.4
k141_17823_8	SARG|gi|944535691|ref|WP_055747198.1|	44.2	52	279	492	3.20e-07	50.1
k141_17823_8	SARG|gi|922777287|ref|WP_053374995.1|	45.1	51	279	492	7.62e-07	48.9
k141_17823_8	SARG|gi|1043542993|ref|WP_065386235.1|	45.1	51	279	492	1.02e-06	48.5
k141_17823_8	SARG|AJ579365.gene.p01	39.2	51	279	492	1.81e-06	47.8
k141_17823_8	SARG|gi|506326044|ref|WP_015845803.1|	42.3	52	279	492	1.81e-06	47.8
k141_17823_9	SARG|gb|AAK76137.1|ARO:3000024|patA	26.9	212	256	564	1.69e-14	71.6
k141_17823_9	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	26.1	199	256	504	2.20e-10	59.3
k141_17823_9	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	24.5	216	256	505	1.30e-09	57.0
k141_17823_9	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	24.3	218	256	524	1.11e-06	48.1
k141_17823_9	SARG|gi|514904648|ref|WP_016630030.1|	24.6	195	256	498	3.47e-06	46.6
k141_17823_9	SARG|gi|514883218|ref|WP_016615053.1|	24.9	197	256	498	4.63e-06	46.2
k141_17823_9	SARG|gi|488303094|ref|WP_002374069.1|	24.9	197	256	498	4.63e-06	46.2
k141_17823_9	SARG|gi|895819918|ref|WP_048943810.1|	24.9	197	256	498	6.19e-06	45.8
k141_17823_9	SARG|gi|727118387|ref|WP_033626720.1|	24.9	197	256	498	6.19e-06	45.8
k141_17823_9	SARG|gi|498521217|ref|WP_010821069.1|	24.9	197	256	498	6.19e-06	45.8
k141_67156_2	SARG|gb|AAK76137.1|ARO:3000024|patA	27.0	248	273	564	2.10e-15	74.7
k141_67156_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.7	231	273	575	1.71e-14	72.0
k141_67156_2	SARG|gi|655413091|ref|WP_028811890.1|	26.8	235	273	603	6.16e-13	67.4
k141_67156_2	SARG|gi|930482089|ref|WP_054228897.1|	25.3	233	273	599	8.26e-13	67.0
k141_67156_2	SARG|gi|985844137|ref|WP_060895163.1|	25.3	233	273	599	8.26e-13	67.0
k141_67156_2	SARG|gi|493394434|ref|WP_006350564.1|	25.2	234	273	602	8.28e-13	67.0
k141_67156_2	SARG|gi|739906046|ref|WP_037756452.1|	25.3	229	273	620	2.73e-12	65.5
k141_67156_2	SARG|gi|516574297|ref|WP_017949361.1|	25.3	229	273	620	2.73e-12	65.5
k141_67156_2	SARG|gi|943938624|ref|WP_055567802.1|	25.5	235	273	602	4.88e-12	64.7
k141_67156_2	SARG|gi|928900436|ref|WP_053931243.1|	25.0	232	273	600	6.55e-12	64.3
k141_46802_4	megares|MEG_727|Drugs|beta-lactam|Class_C_betalactamases|AMPC_1	36.2	401	411	415	1.23e-85	266
k141_46802_6	SARG|gb|CAE00499.1|ARO:3003835|cdeA	23.3	408	456	441	3.39e-18	85.5
k141_46802_6	SARG|HE999704.1.gene3064.p01	31.3	192	456	241	2.15e-14	71.6
k141_46802_6	SARG|gi|441475675|emb|CCQ25429.1|	36.2	105	456	211	7.89e-09	54.7
k141_74279_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	32.2	236	301	370	4.18e-28	110
k141_74279_3	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	32.6	215	301	357	1.76e-27	108
k141_74279_3	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	32.6	215	301	357	1.76e-27	108
k141_74279_3	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	33.6	241	301	364	7.10e-27	107
k141_74279_3	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	33.6	241	301	364	7.10e-27	107
k141_74279_3	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.3	240	301	354	1.63e-26	105
k141_74279_3	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.8	240	301	352	5.78e-26	104
k141_74279_3	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	32.1	240	301	361	1.25e-25	103
k141_74279_3	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	32.1	240	301	361	1.25e-25	103
k141_74279_3	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.8	240	301	376	2.07e-25	103
k141_74279_8	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.3	242	1059	364	6.41e-17	82.8
k141_74279_8	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.3	242	1059	364	6.41e-17	82.8
k141_74279_8	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.6	119	1059	223	8.01e-09	56.2
k141_74279_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.3	116	1059	219	8.22e-08	53.1
k141_74279_8	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	20.4	226	1059	359	1.75e-07	53.5
k141_74279_8	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	27.6	116	1059	231	5.59e-07	50.8
k141_27961_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	33.2	575	583	575	2.84e-102	320
k141_27961_2	SARG|gb|AAK76137.1|ARO:3000024|patA	34.9	522	583	564	6.38e-101	316
k141_27961_2	SARG|gb|AAK76136.1|ARO:3000025|patB	30.2	487	583	588	5.04e-68	230
k141_27961_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.4	487	583	664	1.60e-67	230
k141_27961_2	SARG|gi|1045390184|ref|WP_065479071.1|	28.8	528	583	605	3.68e-61	212
k141_27961_2	SARG|gi|739906046|ref|WP_037756452.1|	28.1	537	583	620	6.69e-61	211
k141_27961_2	SARG|gi|516574297|ref|WP_017949361.1|	28.3	537	583	620	6.69e-61	211
k141_27961_2	SARG|gi|948137056|ref|WP_056795395.1|	29.3	532	583	602	1.79e-60	210
k141_27961_2	SARG|gi|764446018|ref|WP_044369325.1|	29.0	528	583	605	1.89e-60	210
k141_27961_2	SARG|gi|695842130|ref|WP_032755430.1|	28.6	528	583	603	4.84e-60	209
k141_31285_1	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	30.9	123	172	291	3.07e-11	59.3
k141_31285_1	CARD|gb|CAA79966.1|ARO:3003665|NmcR	31.1	132	172	295	2.44e-09	53.9
k141_5895_8	SARG|HE999704.1.gene3064.p01	26.5	181	212	241	1.48e-12	63.5
k141_5895_8	SARG|gi|441475675|emb|CCQ25429.1|	34.0	94	212	211	7.51e-09	52.8
k141_17984_2	SARG|gi|542061059|gb|ERI11611.1|	36.7	305	324	316	4.70e-48	162
k141_17984_2	SARG|ABB80128	36.1	305	324	306	1.01e-47	161
k141_17984_2	SARG|P42332	35.7	305	324	306	2.81e-47	160
k141_17984_2	SARG|AAD21213	35.7	305	324	306	2.81e-47	160
k141_17984_2	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	35.7	305	324	306	2.81e-47	160
k141_17984_2	SARG|gi|510143239|gb|AGN36970.1|	35.7	305	324	313	3.36e-47	160
k141_17984_2	SARG|gi|445996710|ref|WP_000074565.1|	35.9	306	324	309	1.66e-46	158
k141_17984_2	SARG|gi|895736250|emb|COF64653.1|	35.9	306	324	309	3.28e-46	157
k141_17984_2	SARG|gi|507023808|ref|WP_016095885.1|	35.9	309	324	309	3.28e-46	157
k141_17984_2	SARG|gi|445996714|ref|WP_000074569.1|	35.9	306	324	309	3.28e-46	157
k141_67228_1	SARG|gi|542061059|gb|ERI11611.1|	38.6	70	225	316	1.10e-09	56.2
k141_67228_1	SARG|gi|500194536|ref|WP_011867743.1|	33.3	81	225	306	5.31e-08	51.2
k141_67228_1	SARG|gi|507035724|ref|WP_016107411.1|	35.3	68	225	309	5.35e-08	51.2
k141_67228_1	SARG|gi|488120365|ref|WP_002191762.1|	35.3	68	225	309	5.35e-08	51.2
k141_67228_1	SARG|gi|445996708|ref|WP_000074563.1|	35.3	68	225	309	5.35e-08	51.2
k141_67228_1	SARG|gi|445996695|ref|WP_000074550.1|	35.3	68	225	309	5.35e-08	51.2
k141_67228_1	SARG|gi|445996698|ref|WP_000074553.1|	35.3	68	225	309	5.35e-08	51.2
k141_67228_1	SARG|gi|488130770|ref|WP_002201978.1|	35.3	68	225	309	5.35e-08	51.2
k141_67228_1	SARG|gi|488042066|ref|WP_002113463.1|	35.3	68	225	309	5.35e-08	51.2
k141_67228_1	SARG|gi|507023808|ref|WP_016095885.1|	35.3	68	225	309	5.35e-08	51.2
k141_35014_1	SARG|YP_001571041	29.6	233	235	648	6.92e-17	78.2
k141_35014_1	SARG|gi|960873409|ref|WP_058345546.1|	29.6	233	235	648	6.92e-17	78.2
k141_35014_1	SARG|gi|740610794|ref|WP_038396317.1|	29.6	233	235	648	1.72e-16	77.0
k141_35014_1	SARG|gi|1032819400|ref|WP_064325534.1|	28.8	233	235	646	7.78e-16	75.1
k141_35014_1	SARG|gi|922019548|ref|WP_053299973.1|	30.0	233	235	648	7.79e-16	75.1
k141_35014_1	SARG|gi|896325272|ref|WP_049294291.1|	30.2	215	235	648	7.79e-16	75.1
k141_35014_1	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	27.4	219	235	255	9.08e-16	73.2
k141_35014_1	SARG|gi|1016942913|ref|WP_063144441.1|	29.2	233	235	646	1.42e-15	74.3
k141_35014_1	SARG|gi|981224618|ref|WP_059445588.1|	29.2	233	235	646	1.42e-15	74.3
k141_35014_1	SARG|gi|836585048|ref|WP_047742322.1|	29.2	233	235	646	1.42e-15	74.3
k141_1079_6	CARD|gb|BAA15221.2|ARO:3000263|marA	31.5	92	528	127	1.15e-09	55.5
k141_46944_4	SARG|gi|542061059|gb|ERI11611.1|	31.2	247	344	316	7.38e-21	90.5
k141_46944_4	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.3	244	344	307	3.15e-20	88.6
k141_46944_4	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	23.5	281	344	293	1.38e-15	75.1
k141_46944_4	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.8	245	344	574	4.54e-14	72.0
k141_46944_4	SARG|gb|AAK76137.1|ARO:3000024|patA	28.6	224	344	564	1.46e-11	64.3
k141_46944_4	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	228	344	655	3.53e-08	53.9
k141_46944_4	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	228	344	655	3.53e-08	53.9
k141_46944_4	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.1	210	344	362	1.36e-07	51.6
k141_46944_4	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.0	228	344	655	2.56e-07	51.2
k141_46944_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.0	228	344	655	3.40e-07	50.8
k141_46944_5	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.5	226	249	574	7.33e-13	66.6
k141_9143_5	SARG|Q08425	26.0	447	503	641	4.52e-28	117
k141_9143_5	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.0	447	503	657	4.73e-28	117
k141_9143_5	SARG|Z21523.gene.p01	26.0	447	503	657	4.73e-28	117
k141_9143_5	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.0	447	503	654	6.29e-28	116
k141_9143_5	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.0	447	503	670	6.56e-28	116
k141_9143_5	SARG|AAB51122	26.0	447	503	670	6.56e-28	116
k141_9143_5	SARG|Q52360	25.3	442	503	641	8.41e-27	113
k141_9143_5	SARG|P70882	25.3	442	503	641	8.41e-27	113
k141_9143_5	SARG|BAD46890	25.3	442	503	657	8.78e-27	113
k141_9143_5	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	24.9	442	503	641	2.70e-26	111
k141_25948_1	SARG|gi|657888313|ref|WP_029592374.1|	48.6	107	108	648	5.04e-27	102
k141_25948_1	SARG|gi|639225329|ref|WP_024561799.1|	48.6	107	108	648	5.04e-27	102
k141_25948_1	SARG|gi|639218559|ref|WP_024556062.1|	48.6	107	108	648	5.04e-27	102
k141_25948_1	SARG|gi|896325272|ref|WP_049294291.1|	47.7	107	108	648	2.39e-26	100
k141_25948_1	SARG|gi|639216333|ref|WP_024554080.1|	47.7	107	108	648	2.39e-26	100
k141_25948_1	SARG|gi|446110307|ref|WP_000188162.1|	47.7	107	108	648	3.27e-26	100
k141_25948_1	SARG|gi|754724054|ref|WP_042095806.1|	46.7	107	108	648	4.46e-26	99.8
k141_25948_1	SARG|YP_309843	46.7	107	108	648	4.46e-26	99.8
k141_25948_1	SARG|gi|693238509|ref|WP_032348033.1|	46.7	107	108	648	4.46e-26	99.8
k141_25948_1	SARG|gi|485870849|ref|WP_001467831.1|	46.7	107	108	648	4.46e-26	99.8
k141_62082_5	SARG|gi|896325272|ref|WP_049294291.1|	37.3	233	248	648	5.96e-41	147
k141_62082_5	SARG|gi|803568669|ref|WP_046077412.1|	37.6	229	248	648	2.94e-40	145
k141_62082_5	SARG|gi|446110352|ref|WP_000188207.1|	37.6	229	248	648	2.94e-40	145
k141_62082_5	SARG|YP_002382193	37.6	229	248	648	2.94e-40	145
k141_62082_5	SARG|gi|803575554|ref|WP_046081557.1|	37.6	229	248	648	2.94e-40	145
k141_62082_5	SARG|gi|446110351|ref|WP_000188206.1|	37.6	229	248	648	2.94e-40	145
k141_62082_5	SARG|gi|639216333|ref|WP_024554080.1|	36.9	233	248	648	4.05e-40	145
k141_62082_5	SARG|gi|1022688710|ref|WP_063443532.1|	37.0	227	248	648	5.57e-40	144
k141_62082_5	SARG|gi|639225329|ref|WP_024561799.1|	36.2	232	248	648	7.67e-40	144
k141_62082_5	SARG|gi|895981299|ref|WP_049056431.1|	36.6	227	248	648	7.67e-40	144
k141_74420_1	NCBI|AAD44693.1|1|1|mtrA_Ngon|mtrA_Ngon||1|EFFLUX|EFFLUX|efflux_transporter_MtrCDE_transcriptional_activator_MtrA|AMR|efflux	30.2	86	203	301	3.80e-12	62.8
k141_4546_1	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	48.0	202	203	223	2.70e-67	204
k141_4546_1	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.8	201	203	229	1.88e-32	115
k141_4546_1	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	29.5	207	203	233	2.91e-28	105
k141_4546_1	CARD|gb|AAG05188.1|ARO:3005068|ParR	28.9	201	203	235	6.01e-28	104
k141_4546_1	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.6	206	203	231	2.14e-27	102
k141_4546_1	CARD|gb|ADM92605.1|ARO:3000553|adeR	33.0	206	203	247	4.24e-27	102
k141_4546_1	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	28.9	204	203	225	3.23e-24	94.4
k141_4546_1	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	27.4	215	203	252	6.36e-19	80.9
k141_4582_3	SARG|gb|ABA71733.1|ARO:3002972|vanTG	40.0	370	375	712	5.24e-78	253
k141_4582_3	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	38.0	371	375	366	1.40e-73	232
k141_4582_3	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	37.2	376	375	712	1.34e-70	233
k141_4582_3	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	37.3	370	375	711	3.93e-65	218
k141_4582_3	SARG|AAY67970	34.6	367	375	698	6.37e-63	212
k141_4582_3	SARG|AF162694.1.gene4.p01	34.5	371	375	698	8.86e-63	212
k141_4582_3	SARG|gi|657686198|ref|WP_029487032.1|	34.5	371	375	698	8.86e-63	212
k141_4582_3	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	38.0	358	375	700	9.13e-63	212
k141_4582_3	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	37.5	371	375	700	1.27e-61	209
k141_4582_3	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	37.1	367	375	700	9.17e-61	206
k141_1271_11	SARG|gi|446048013|ref|WP_000125868.1|	29.6	223	514	648	2.34e-24	105
k141_1271_11	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.8	230	514	664	2.33e-14	74.7
k141_65781_1	SARG|gi|944009777|ref|WP_055601444.1|	58.0	112	113	628	2.56e-34	123
k141_65781_1	SARG|gi|695887424|ref|WP_032788534.1|	58.7	104	113	605	3.24e-34	122
k141_65781_1	SARG|gi|497748188|ref|WP_010062372.1|	58.7	104	113	605	3.24e-34	122
k141_65781_1	SARG|gi|764446018|ref|WP_044369325.1|	58.7	104	113	605	3.24e-34	122
k141_65781_1	SARG|gi|695865802|ref|WP_032778631.1|	58.7	104	113	605	3.24e-34	122
k141_65781_1	SARG|gi|1045390184|ref|WP_065479071.1|	58.7	104	113	605	3.24e-34	122
k141_65781_1	SARG|gi|664180077|ref|WP_030714054.1|	58.7	104	113	605	3.24e-34	122
k141_65781_1	SARG|gi|1033217078|gb|OAR27197.1|	60.6	104	113	601	4.38e-34	122
k141_65781_1	SARG|gi|695842130|ref|WP_032755430.1|	58.7	104	113	603	6.07e-34	122
k141_65781_1	SARG|gi|505420018|ref|WP_015607120.1|	58.7	104	113	603	6.07e-34	122
k141_65781_3	SARG|gi|693076086|ref|WP_032238993.1|	37.1	124	410	648	1.12e-06	49.7
k141_47073_5	SARG|gi|921979807|ref|WP_053271336.1|	35.1	205	253	648	2.74e-29	114
k141_47073_5	SARG|gi|507050365|ref|WP_016121371.1|	30.5	223	253	309	1.92e-26	103
k141_47073_5	SARG|gi|488053456|ref|WP_002124853.1|	30.5	223	253	309	2.67e-26	103
k141_47073_5	SARG|gi|488120365|ref|WP_002191762.1|	30.5	223	253	309	3.71e-26	102
k141_47073_5	SARG|gi|488068784|ref|WP_002140181.1|	30.5	223	253	309	3.71e-26	102
k141_47073_5	SARG|gi|507023808|ref|WP_016095885.1|	30.0	223	253	309	5.16e-26	102
k141_47073_5	SARG|gi|488067981|ref|WP_002139378.1|	30.0	223	253	309	7.18e-26	102
k141_47073_5	SARG|gi|487936534|ref|WP_002010000.1|	30.0	223	253	309	7.18e-26	102
k141_47073_5	SARG|gi|507055561|ref|WP_016126482.1|	30.5	223	253	309	9.99e-26	101
k141_47073_5	SARG|gi|447057510|ref|WP_001134766.1|	29.7	222	253	309	9.99e-26	101
k141_47076_2	SARG|gi|851913025|ref|WP_048215946.1|	37.2	234	253	648	3.20e-39	142
k141_47076_2	SARG|gi|696361545|ref|WP_032936694.1|	35.6	261	253	648	3.20e-39	142
k141_47076_2	SARG|gi|489930965|ref|WP_003834285.1|	37.2	234	253	648	3.20e-39	142
k141_47076_2	SARG|gi|696368937|ref|WP_032943949.1|	37.5	232	253	648	4.39e-39	142
k141_47076_2	SARG|gi|489936909|ref|WP_003840216.1|	37.2	234	253	648	4.39e-39	142
k141_47076_2	SARG|gi|507079862|ref|WP_016150620.1|	37.2	234	253	648	4.39e-39	142
k141_47076_2	SARG|gi|949791377|ref|WP_057104572.1|	37.2	234	253	648	4.39e-39	142
k141_47076_2	SARG|gi|936194420|ref|WP_054528571.1|	37.2	234	253	648	6.04e-39	142
k141_47076_2	SARG|YP_002850060	37.2	234	253	648	6.04e-39	142
k141_47076_2	SARG|gi|491270241|ref|WP_005128370.1|	35.2	261	253	648	8.29e-39	141
k141_40371_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	30.1	229	226	225	9.44e-32	114
k141_40371_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	30.1	226	226	225	3.69e-31	113
k141_40371_2	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	28.6	224	226	225	8.32e-24	94.0
k141_40371_2	CARD|gb|AAG05188.1|ARO:3005068|ParR	28.9	225	226	235	7.87e-22	89.0
k141_40371_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.1	227	226	228	7.09e-21	86.3
k141_40371_3	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	21.7	235	300	357	7.02e-10	58.2
k141_40371_3	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	21.7	235	300	357	7.02e-10	58.2
k141_40371_4	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	44.6	224	224	255	9.39e-63	195
k141_40371_4	SARG|Q83LR7	45.9	220	224	648	9.68e-57	189
k141_40371_4	SARG|gi|647325472|ref|WP_025760953.1|	45.9	220	224	648	9.68e-57	189
k141_40371_4	SARG|gi|647323678|ref|WP_025760497.1|	45.9	220	224	648	9.68e-57	189
k141_40371_4	SARG|gi|736472622|ref|WP_034494292.1|	44.8	221	224	648	2.62e-56	188
k141_40371_4	SARG|gi|1035706844|ref|WP_064548272.1|	45.2	221	224	648	2.62e-56	188
k141_40371_4	SARG|gi|446110305|ref|WP_000188160.1|	45.5	220	224	648	3.64e-56	187
k141_40371_4	SARG|gi|1035670474|ref|WP_064517458.1|	44.3	221	224	648	1.37e-55	186
k141_40371_4	SARG|gi|1035717981|ref|WP_064557480.1|	44.3	221	224	648	1.37e-55	186
k141_40371_4	SARG|gi|391288090|gb|EIQ46599.1|	45.0	220	224	645	1.83e-55	186
k141_31577_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	47.7	241	252	664	3.17e-74	237
k141_31577_1	SARG|gb|AAK76136.1|ARO:3000025|patB	47.1	242	252	588	3.12e-72	230
k141_31577_1	SARG|gi|953808775|ref|WP_058042812.1|	46.5	245	252	608	1.83e-71	228
k141_31577_1	SARG|gi|817122037|ref|WP_046494699.1|	46.4	239	252	613	3.97e-71	228
k141_31577_1	SARG|gi|702897513|ref|WP_033300957.1|	47.9	238	252	601	8.64e-71	226
k141_31577_1	SARG|gi|664352659|ref|WP_030880307.1|	46.3	240	252	601	1.70e-70	226
k141_31577_1	SARG|gi|662754041|ref|WP_030125200.1|	46.7	240	252	601	1.70e-70	226
k141_31577_1	SARG|gi|505389066|ref|WP_015576168.1|	46.7	240	252	601	1.70e-70	226
k141_31577_1	SARG|gi|664100597|ref|WP_030638327.1|	46.3	240	252	601	2.39e-70	225
k141_31577_1	SARG|gi|503923650|ref|WP_014157644.1|	46.3	240	252	601	2.39e-70	225
k141_57432_5	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	3.06e-95	301
k141_57432_5	SARG|gb|AKA86814|ARO:3003746|optrA	35.3	496	519	655	3.06e-95	301
k141_57432_5	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	8.46e-95	300
k141_57432_5	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	8.46e-95	300
k141_57432_5	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	8.46e-95	300
k141_57432_5	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	1.19e-94	300
k141_57432_5	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	1.67e-94	300
k141_57432_5	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.1	496	519	655	3.29e-94	299
k141_57432_5	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.1	496	519	655	6.48e-94	298
k141_57432_5	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.1	496	519	655	6.48e-94	298
k141_64311_9	SARG|gb|AAV85982.1|ARO:3000535|macB	31.8	233	352	644	6.16e-23	99.0
k141_64311_9	SARG|gi|696368937|ref|WP_032943949.1|	32.5	231	352	648	6.19e-23	99.0
k141_64311_9	SARG|gi|851913025|ref|WP_048215946.1|	32.5	231	352	648	6.19e-23	99.0
k141_64311_9	SARG|YP_002850060	32.5	231	352	648	6.19e-23	99.0
k141_64311_9	SARG|gi|489930965|ref|WP_003834285.1|	32.5	231	352	648	6.19e-23	99.0
k141_64311_9	SARG|gi|696361545|ref|WP_032936694.1|	32.5	231	352	648	8.34e-23	98.6
k141_64311_9	SARG|gi|489936909|ref|WP_003840216.1|	32.5	231	352	648	8.34e-23	98.6
k141_64311_9	SARG|gi|507079862|ref|WP_016150620.1|	32.5	231	352	648	8.34e-23	98.6
k141_64311_9	SARG|gi|949791377|ref|WP_057104572.1|	32.5	231	352	648	8.34e-23	98.6
k141_64311_9	SARG|gi|936194420|ref|WP_054528571.1|	32.5	231	352	648	1.51e-22	97.8
k141_40493_6	SARG|YP_001605795	28.9	388	399	562	8.47e-22	96.3
k141_40493_6	SARG|gi|896190680|ref|WP_049199932.1|	27.4	383	399	563	3.70e-21	94.4
k141_40493_6	SARG|AAS61092	28.2	393	399	563	3.70e-21	94.4
k141_40493_6	SARG|gi|1001786599|ref|WP_061324791.1|	27.3	388	399	563	8.93e-21	93.2
k141_40493_6	SARG|YP_001477377	26.4	383	399	563	8.93e-21	93.2
k141_40493_6	SARG|YP_001401994	28.0	393	399	563	2.89e-20	91.7
k141_40493_6	SARG|ZP_04638974	26.3	392	399	563	1.29e-18	86.7
k141_40493_6	SARG|gi|740410309|ref|WP_038243756.1|	26.2	386	399	563	1.29e-18	86.7
k141_40493_6	SARG|ZP_04612557	26.1	383	399	543	2.96e-18	85.5
k141_40493_6	SARG|ZP_04630103	26.2	385	399	543	2.96e-18	85.5
k141_31639_5	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	32.8	189	684	722	3.21e-20	94.4
k141_18469_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	43.2	227	234	225	1.40e-60	189
k141_18469_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	43.2	227	234	225	1.40e-60	189
k141_18469_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.8	228	234	231	4.76e-46	152
k141_18469_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.3	228	234	232	1.20e-40	138
k141_18469_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.3	228	234	232	1.20e-40	138
k141_18469_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.0	226	234	229	2.20e-40	137
k141_18469_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.2	224	234	219	2.37e-40	137
k141_18469_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.2	227	234	231	4.62e-40	136
k141_18469_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.3	230	234	232	4.75e-40	136
k141_18469_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.2	228	234	235	1.44e-39	135
k141_18469_3	SARG|gb|AAG05187.1|ARO:3005067|ParS	34.8	66	121	428	3.79e-07	46.2
k141_29687_6	SARG|gb|CAE00499.1|ARO:3003835|cdeA	40.9	435	451	441	7.81e-111	333
k141_38601_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.1	162	583	255	1.16e-14	73.2
k141_4841_7	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.9	210	293	255	9.19e-26	101
k141_4841_7	SARG|gi|746243059|ref|WP_039291473.1|	32.6	236	293	648	1.57e-25	105
k141_4841_7	SARG|gi|746253210|ref|WP_039301529.1|	32.6	236	293	648	2.13e-25	104
k141_4841_7	SARG|gi|1001720867|ref|WP_061274204.1|	32.6	236	293	648	2.13e-25	104
k141_4841_7	SARG|gi|565651791|ref|WP_023899061.1|	33.8	234	293	647	2.88e-25	104
k141_4841_7	SARG|gi|1035670474|ref|WP_064517458.1|	31.9	273	293	648	2.88e-25	104
k141_4841_7	SARG|gi|1035717981|ref|WP_064557480.1|	31.9	273	293	648	2.88e-25	104
k141_4841_7	SARG|gi|495736522|ref|WP_008461101.1|	32.6	236	293	648	3.90e-25	103
k141_4841_7	SARG|Q83LR7	32.6	233	293	648	3.90e-25	103
k141_4841_7	SARG|gi|647325472|ref|WP_025760953.1|	32.6	233	293	648	3.90e-25	103
k141_8107_1	SARG|NP_878015	34.6	240	297	322	9.26e-28	108
k141_8107_1	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	33.8	240	297	322	6.61e-27	106
k141_8107_1	SARG|AAY52004	33.8	240	297	322	6.50e-26	103
k141_8107_1	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	32.5	240	297	351	1.38e-25	103
k141_8107_1	megares|MEG_7399|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_1	32.9	228	297	237	9.69e-25	98.6
k141_8107_1	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	32.1	240	297	343	2.26e-24	99.8
k141_8107_1	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	32.1	240	297	348	2.42e-24	99.8
k141_8107_1	SARG|gi|740152780|ref|WP_037997109.1|	31.4	239	297	322	1.17e-23	97.4
k141_8107_1	SARG|AAD51059	30.6	255	297	323	1.56e-22	94.4
k141_8107_1	SARG|AAR37059	32.3	220	297	323	1.46e-21	91.7
k141_4858_3	SARG|ZP_04679156	22.9	389	453	451	1.98e-31	124
k141_65928_5	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.3	232	338	255	1.57e-28	110
k141_65928_5	SARG|gi|545248218|ref|WP_021546584.1|	28.0	271	338	648	4.43e-24	102
k141_65928_5	SARG|gi|766974935|ref|WP_044866868.1|	30.7	218	338	648	1.98e-23	100
k141_65928_5	SARG|Q83LR7	31.7	218	338	648	3.60e-23	99.4
k141_65928_5	SARG|gi|647325472|ref|WP_025760953.1|	31.7	218	338	648	3.60e-23	99.4
k141_65928_5	SARG|gi|647323678|ref|WP_025760497.1|	31.7	218	338	648	3.60e-23	99.4
k141_65928_5	SARG|gi|446110295|ref|WP_000188150.1|	27.7	271	338	648	3.60e-23	99.4
k141_65928_5	SARG|gi|979505419|ref|WP_059334195.1|	27.7	271	338	648	4.85e-23	99.0
k141_65928_5	SARG|ZP_04001960	27.7	271	338	648	4.85e-23	99.0
k141_65928_5	SARG|gi|545164255|ref|WP_021518974.1|	27.7	271	338	648	4.85e-23	99.0
k141_28279_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	27.6	76	480	231	1.16e-07	51.6
k141_28279_2	SARG|gi|664556405|ref|WP_031071225.1|	34.3	575	586	602	1.07e-103	324
k141_28279_2	SARG|gi|505420018|ref|WP_015607120.1|	33.2	573	586	603	4.69e-102	320
k141_28279_2	SARG|gi|695865802|ref|WP_032778631.1|	32.5	579	586	605	4.95e-102	320
k141_28279_2	SARG|AF170880.4.gene1.p01	33.9	575	586	615	9.06e-102	320
k141_28279_2	SARG|gi|695842130|ref|WP_032755430.1|	33.2	573	586	603	1.30e-101	319
k141_28279_2	SARG|gi|558888514|ref|WP_023543283.1|	33.7	575	586	615	2.52e-101	318
k141_28279_2	SARG|gi|664042835|ref|WP_030582300.1|	33.6	571	586	604	2.65e-101	318
k141_28279_2	SARG|gi|1045390184|ref|WP_065479071.1|	32.8	576	586	605	2.72e-101	318
k141_28279_2	SARG|gi|947982677|ref|WP_056642336.1|	34.6	583	586	626	3.35e-101	318
k141_28279_2	SARG|gi|928900436|ref|WP_053931243.1|	32.8	579	586	600	6.61e-101	317
k141_79934_3	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	58.5	159	160	159	3.83e-61	185
k141_45691_3	SARG|gb|ADZ12699.1|ARO:3005091|RanA	31.0	239	358	258	2.36e-31	118
k141_45691_3	SARG|gi|895865878|ref|WP_048974758.1|	35.6	222	358	646	4.25e-28	114
k141_45691_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.7	220	358	664	5.37e-17	81.3
k141_45691_3	SARG|gb|AAK76136.1|ARO:3000025|patB	26.7	217	358	588	3.83e-16	78.6
k141_45691_3	SARG|gb|CDO61516.1|ARO:3003949|efrB	29.5	200	358	362	9.29e-15	73.6
k141_45691_3	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.7	224	358	579	9.43e-14	71.2
k141_45691_3	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.2	225	358	579	4.00e-13	69.3
k141_45691_5	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	31.3	281	445	355	7.75e-23	98.2
k141_45691_5	SARG|BAE96115	31.3	281	445	355	7.75e-23	98.2
k141_45691_5	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.7	283	445	356	4.65e-20	90.1
k141_45691_5	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	33.0	197	445	209	3.07e-16	76.3
k141_45691_6	SARG|gi|505177635|ref|WP_015364737.1|	25.0	440	461	451	1.44e-37	141
k141_45691_6	SARG|ZP_04679156	25.9	440	461	451	2.74e-37	140
k141_45691_6	SARG|gi|488374619|ref|WP_002444004.1|	25.2	432	461	452	1.89e-36	138
k141_45691_6	SARG|gb|CAE00499.1|ARO:3003835|cdeA	25.3	415	461	441	3.59e-34	132
k141_44188_2	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.2	379	750	1197	2.38e-38	152
k141_44188_2	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.1	267	750	359	3.62e-18	85.9
k141_44188_2	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	24.4	316	750	364	2.33e-15	77.4
k141_44188_2	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	24.4	316	750	364	2.33e-15	77.4
k141_44188_2	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.0	224	750	352	3.74e-15	76.6
k141_44188_2	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.0	224	750	354	6.80e-15	75.9
k141_44188_2	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.0	224	750	376	8.16e-15	75.9
k141_44188_2	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	25.0	224	750	376	8.16e-15	75.9
k141_44188_2	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.1	224	750	354	6.92e-14	72.8
k141_44188_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	29.5	112	750	232	1.96e-08	54.7
k141_44188_4	SARG|gi|489929427|ref|WP_003832751.1|	23.4	350	450	457	6.38e-17	81.6
k141_44188_4	SARG|YP_002849300	23.4	350	450	457	8.51e-17	81.3
k141_44188_4	SARG|gi|851908704|ref|WP_048214273.1|	23.1	350	450	457	8.51e-17	81.3
k141_44188_4	SARG|YP_001176513	23.3	352	450	457	1.14e-16	80.9
k141_44188_4	SARG|gi|851915138|ref|WP_048216502.1|	23.1	350	450	457	1.52e-16	80.5
k141_44188_4	SARG|gi|696368298|ref|WP_032943310.1|	23.4	354	450	457	2.02e-16	80.1
k141_44188_4	SARG|gi|487511179|ref|WP_001706772.1|	22.4	348	450	457	3.60e-16	79.3
k141_44188_4	SARG|YP_001570595	23.4	359	450	457	3.60e-16	79.3
k141_44188_4	SARG|gi|757799242|ref|WP_043016444.1|	22.9	350	450	457	3.60e-16	79.3
k141_44188_4	SARG|gi|754952496|ref|WP_042308660.1|	23.4	350	450	457	4.80e-16	79.0
k141_23138_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.6	125	499	228	9.37e-07	48.9
k141_23138_3	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.9	86	499	204	4.34e-06	46.6
k141_5045_7	megares|MEG_7167|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	45.4	130	142	639	8.03e-31	114
k141_5045_7	SARG|FN594949.1.gene24.p01	45.4	130	142	640	8.04e-31	114
k141_5045_7	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	45.4	130	142	640	8.04e-31	114
k141_5045_7	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	45.4	130	142	629	2.76e-30	113
k141_5045_7	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	45.4	130	142	629	2.76e-30	113
k141_5045_7	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	45.4	130	142	629	2.76e-30	113
k141_5045_7	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	45.4	130	142	629	2.76e-30	113
k141_5045_7	NCBI|WP_013646121.1|1|1|tet(O/W/32/O)|tet(O/W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(O/W/32/O)|AMR|tetracycline	45.4	130	142	639	2.81e-30	113
k141_5045_7	SARG|ABF69686	45.4	130	142	639	2.81e-30	113
k141_5045_7	SARG|ABG81258	45.4	130	142	639	2.81e-30	113
k141_3185_3	SARG|gi|515720450|ref|WP_017153050.1|	44.0	75	191	210	1.23e-11	60.1
k141_3185_3	SARG|gi|670466162|ref|WP_031414939.1|	40.7	86	191	206	2.23e-11	59.3
k141_3185_3	SARG|gi|1028848471|ref|WP_064017434.1|	39.7	73	191	206	8.08e-11	57.8
k141_3185_3	SARG|AF155139.2.gene5.p01	41.4	70	191	206	5.52e-10	55.5
k141_21502_4	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	23.8	320	1112	722	3.32e-17	85.9
k141_11540_1	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	32.1	78	160	341	6.94e-07	46.6
k141_11540_2	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	48.1	131	137	341	6.72e-35	122
k141_11540_3	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	49.4	249	256	255	3.44e-84	251
k141_11540_3	SARG|gi|696361545|ref|WP_032936694.1|	39.0	251	256	648	7.48e-59	196
k141_11540_3	SARG|YP_002850060	40.7	221	256	648	1.04e-58	196
k141_11540_3	SARG|gi|696368937|ref|WP_032943949.1|	40.7	221	256	648	1.45e-58	195
k141_11540_3	SARG|gi|851913025|ref|WP_048215946.1|	40.7	221	256	648	1.45e-58	195
k141_11540_3	SARG|gi|489936909|ref|WP_003840216.1|	40.7	221	256	648	1.45e-58	195
k141_11540_3	SARG|gi|507079862|ref|WP_016150620.1|	40.7	221	256	648	1.45e-58	195
k141_11540_3	SARG|gi|949791377|ref|WP_057104572.1|	40.7	221	256	648	1.45e-58	195
k141_11540_3	SARG|gi|489930965|ref|WP_003834285.1|	40.7	221	256	648	1.45e-58	195
k141_11540_3	SARG|gi|922960663|ref|WP_053388845.1|	39.6	235	256	648	1.45e-58	195
k141_11540_4	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	28.1	675	667	641	1.17e-50	185
k141_75008_5	SARG|gb|AAK76136.1|ARO:3000025|patB	27.2	492	545	588	2.74e-47	172
k141_75008_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	24.2	451	545	664	3.68e-38	147
k141_75008_5	SARG|gb|AAK76137.1|ARO:3000024|patA	23.3	484	545	564	2.53e-29	120
k141_75008_5	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	24.4	516	545	574	1.23e-27	115
k141_75008_5	SARG|gi|446048013|ref|WP_000125868.1|	33.5	221	545	648	7.68e-18	85.9
k141_75008_5	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	29.9	187	545	505	8.27e-14	72.8
k141_75008_5	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	29.4	187	545	504	3.19e-12	67.8
k141_75008_6	SARG|gi|928900436|ref|WP_053931243.1|	26.4	535	577	600	1.15e-39	152
k141_75008_6	SARG|gi|664579989|ref|WP_031094015.1|	26.4	535	577	601	1.16e-39	152
k141_75008_6	SARG|gi|917229923|ref|WP_051836635.1|	24.5	576	577	620	2.95e-38	148
k141_75008_6	SARG|gi|558888514|ref|WP_023543283.1|	26.0	572	577	615	9.55e-38	146
k141_75008_6	SARG|gi|917172177|ref|WP_051778889.1|	24.8	568	577	620	1.35e-37	146
k141_75008_6	SARG|gi|516795764|ref|WP_018105258.1|	25.9	541	577	601	2.10e-37	145
k141_75008_6	SARG|gi|917155568|ref|WP_051762280.1|	24.8	568	577	620	3.35e-37	145
k141_75008_6	SARG|gi|919568551|ref|WP_052871170.1|	24.6	568	577	620	3.35e-37	145
k141_75008_6	SARG|gi|917166849|ref|WP_051773561.1|	24.8	568	577	620	3.35e-37	145
k141_75008_6	SARG|gi|517347347|ref|WP_018522839.1|	25.7	541	577	601	3.86e-37	144
k141_77881_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	45.2	217	221	231	2.43e-59	185
k141_77881_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.2	217	221	231	2.43e-59	185
k141_77881_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.0	218	221	232	5.03e-59	184
k141_77881_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.0	218	221	232	5.03e-59	184
k141_77881_4	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.3	221	221	233	2.95e-58	182
k141_77881_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.9	221	221	231	7.87e-58	181
k141_77881_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	44.8	223	221	239	1.42e-57	181
k141_77881_4	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.9	219	221	235	1.78e-57	181
k141_77881_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	42.6	216	221	229	1.69e-56	178
k141_77881_4	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.6	218	221	231	7.21e-56	176
k141_6763_6	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	35.6	222	242	343	4.03e-40	140
k141_6763_6	SARG|YP_001373621	35.0	223	242	318	2.52e-39	137
k141_6763_6	SARG|gi|542061059|gb|ERI11611.1|	34.5	223	242	316	4.75e-39	136
k141_6763_6	SARG|gb|AAA26793|ARO:3003748|oleC	31.3	217	242	325	1.93e-35	127
k141_6763_6	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	31.3	217	242	325	1.93e-35	127
k141_6763_6	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	27.4	230	242	351	2.79e-19	84.3
k141_6763_6	SARG|gb|AAR96051.1|ARO:3002894|otrC	27.4	230	242	351	5.26e-19	83.6
k141_6763_8	SARG|gb|AML99881.1|ARO:3001327|mdtK	27.8	439	457	474	6.11e-30	120
k141_6763_8	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	18.3	443	457	443	2.55e-12	67.4
k141_55887_4	SARG|gi|447195835|ref|WP_001273091.1|	42.9	212	370	306	3.92e-45	156
k141_55887_4	SARG|ZP_04081918	42.5	212	370	306	1.08e-44	155
k141_55887_4	SARG|gi|447195836|ref|WP_001273092.1|	42.5	212	370	306	1.08e-44	155
k141_55887_4	SARG|gi|542061059|gb|ERI11611.1|	41.0	222	370	316	2.71e-44	154
k141_55887_4	SARG|gi|500194536|ref|WP_011867743.1|	40.1	222	370	306	5.83e-44	153
k141_55887_4	SARG|P42332	40.1	222	370	306	8.16e-44	152
k141_55887_4	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	40.1	222	370	306	8.16e-44	152
k141_55887_4	SARG|gi|510143239|gb|AGN36970.1|	40.1	222	370	313	9.70e-44	152
k141_55887_4	SARG|ABB80128	40.1	222	370	306	1.14e-43	152
k141_55887_4	SARG|gi|507044560|ref|WP_016115614.1|	38.7	222	370	306	1.14e-43	152
k141_69552_2	SARG|gb|BAD63613.1|ARO:3002816|clbC	33.5	340	347	350	6.14e-55	182
k141_69552_2	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	34.2	330	347	349	1.62e-50	171
k141_69552_2	SARG|AJ249217.gene.p01	34.2	330	347	349	4.48e-50	169
k141_14610_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.8	565	590	575	4.00e-45	167
k141_14610_4	SARG|gi|496018010|ref|WP_008742581.1|	25.9	517	590	623	3.93e-34	136
k141_14610_4	SARG|gi|739906046|ref|WP_037756452.1|	25.2	528	590	620	1.70e-33	134
k141_14610_4	SARG|gi|516574297|ref|WP_017949361.1|	25.2	528	590	620	2.29e-33	134
k141_14610_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	25.0	557	590	582	3.18e-33	133
k141_14610_4	SARG|gb|AAK76137.1|ARO:3000024|patA	24.6	513	590	564	6.73e-33	132
k141_14610_4	SARG|gi|926351744|ref|WP_053683383.1|	25.4	516	590	648	1.18e-32	132
k141_14610_4	SARG|gi|928900436|ref|WP_053931243.1|	25.5	541	590	600	1.19e-32	131
k141_14610_4	SARG|gi|664579989|ref|WP_031094015.1|	25.5	541	590	601	1.20e-32	131
k141_14610_4	SARG|gi|917203192|ref|WP_051809904.1|	26.2	523	590	620	1.07e-31	129
k141_3410_2	CARD|gb|WKR28567.1|ARO:3007678|IreK	33.5	671	754	718	7.23e-85	283
k141_28681_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.2	131	231	219	3.45e-06	45.4
k141_28681_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.7	86	231	228	8.99e-06	44.3
k141_48927_4	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	28.4	218	233	293	2.38e-33	120
k141_48927_4	SARG|gi|542061059|gb|ERI11611.1|	27.7	242	233	316	4.88e-24	96.7
k141_48927_4	SARG|gi|446026113|ref|WP_000103968.1|	28.5	235	233	306	1.57e-23	95.1
k141_48927_4	SARG|gi|507044560|ref|WP_016115614.1|	28.6	238	233	306	1.55e-22	92.4
k141_48927_4	SARG|ZP_04081918	28.9	235	233	306	2.16e-22	92.0
k141_48927_4	SARG|gi|447195836|ref|WP_001273092.1|	28.9	235	233	306	2.99e-22	91.7
k141_48927_4	SARG|gi|447195835|ref|WP_001273091.1|	28.9	235	233	306	4.15e-22	91.3
k141_48927_4	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.9	225	233	307	8.08e-22	90.5
k141_48927_4	SARG|P42332	30.4	217	233	306	1.53e-21	89.7
k141_48927_4	SARG|AAD21213	30.4	217	233	306	2.12e-21	89.4
k141_13434_25	SARG|HE999704.1.gene3064.p01	25.6	195	454	241	9.05e-17	78.6
k141_13434_25	SARG|gi|441475675|emb|CCQ25429.1|	27.9	140	454	211	6.80e-13	66.6
k141_13434_25	SARG|gi|555139174|gb|ESM81938.1|	21.8	380	454	453	1.46e-12	68.2
k141_29970_6	SARG|B2VGJ3	29.9	278	289	273	3.21e-26	103
k141_29970_6	SARG|Q1LSL8	27.9	280	289	275	3.34e-26	103
k141_29970_6	SARG|YP_001436495	28.7	282	289	272	1.18e-24	99.0
k141_29970_6	SARG|Q6D159	29.3	280	289	272	4.41e-24	97.4
k141_29970_6	SARG|YP_002236533	29.1	285	289	273	4.49e-24	97.4
k141_29970_6	SARG|ZP_03833009	28.9	280	289	272	6.12e-24	97.1
k141_29970_6	SARG|ZP_03945515	26.8	310	289	291	8.51e-24	97.1
k141_29970_6	SARG|YP_001455939	29.7	286	289	272	1.63e-23	95.9
k141_29970_6	SARG|YP_002931998	28.2	287	289	272	2.27e-23	95.5
k141_29970_6	SARG|ZP_03829223	28.6	280	289	272	2.27e-23	95.5
k141_46080_2	SARG|gb|APB03216.1|ARO:3003982|LlmA	61.7	287	289	287	1.45e-142	401
k141_21638_1	SARG|gi|505177635|ref|WP_015364737.1|	27.5	207	210	451	5.10e-16	74.7
k141_21638_1	SARG|ZP_04679156	27.1	207	210	451	3.20e-15	72.4
k141_21638_1	SARG|gi|565830932|ref|WP_023914633.1|	28.1	203	210	451	1.47e-14	70.5
k141_21638_1	SARG|gi|313619623|gb|EFR91268.1|	27.4	215	210	237	1.51e-14	68.9
k141_21638_1	SARG|gi|686155635|ref|WP_031787393.1|	27.1	207	210	451	1.99e-14	70.1
k141_21638_1	SARG|gi|446573718|ref|WP_000651064.1|	26.6	207	210	451	3.67e-14	69.3
k141_21638_1	SARG|gi|487138435|ref|WP_001629863.1|	27.6	203	210	451	4.97e-14	68.9
k141_21638_1	SARG|gi|686448604|ref|WP_031928572.1|	27.1	203	210	451	6.74e-14	68.6
k141_21638_1	SARG|gi|686334333|ref|WP_031881350.1|	27.6	203	210	451	9.14e-14	68.2
k141_21638_1	SARG|gi|686251508|ref|WP_031837026.1|	27.6	203	210	451	9.14e-14	68.2
k141_21638_4	SARG|gi|696411918|ref|WP_032982657.1|	41.2	233	233	647	3.54e-56	188
k141_21638_4	SARG|gi|696402390|ref|WP_032974230.1|	41.2	233	233	647	3.54e-56	188
k141_21638_4	SARG|gi|696423952|ref|WP_032993748.1|	41.2	233	233	647	3.54e-56	188
k141_21638_4	SARG|gi|494938585|ref|WP_007664615.1|	40.8	233	233	647	4.93e-56	187
k141_21638_4	SARG|gi|1035670474|ref|WP_064517458.1|	41.3	230	233	648	4.99e-56	187
k141_21638_4	SARG|gi|974588181|ref|WP_059178476.1|	43.0	221	233	646	9.42e-56	187
k141_21638_4	SARG|gi|495067432|ref|WP_007792257.1|	41.2	233	233	647	9.55e-56	187
k141_21638_4	SARG|gi|803568669|ref|WP_046077412.1|	42.5	221	233	648	9.68e-56	187
k141_21638_4	SARG|gi|446110352|ref|WP_000188207.1|	42.5	221	233	648	9.68e-56	187
k141_21638_4	SARG|YP_002382193	42.5	221	233	648	9.68e-56	187
k141_28760_1	SARG|HE999704.1.gene3064.p01	22.0	168	291	241	3.04e-08	52.4
k141_64763_2	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	51.3	513	513	494	7.38e-168	483
k141_64763_2	SARG|gi|944535691|ref|WP_055747198.1|	49.2	512	513	492	2.38e-163	471
k141_64763_2	SARG|gi|445983920|ref|WP_000061775.1|	48.1	513	513	492	1.36e-162	469
k141_64763_2	SARG|gi|1005577494|ref|WP_061669299.1|	47.9	512	513	492	1.92e-162	469
k141_64763_2	SARG|gi|445983951|ref|WP_000061806.1|	47.6	513	513	492	2.72e-162	468
k141_64763_2	SARG|gi|1027702639|ref|WP_063637955.1|	47.9	512	513	492	2.72e-162	468
k141_64763_2	SARG|gi|498488199|ref|WP_010789887.1|	47.9	512	513	492	3.86e-162	468
k141_64763_2	SARG|gi|445983921|ref|WP_000061776.1|	48.0	513	513	492	5.46e-162	468
k141_64763_2	SARG|gi|926256269|ref|WP_053594535.1|	48.1	514	513	492	7.74e-162	467
k141_64763_2	SARG|gi|496784101|ref|WP_009371362.1|	48.2	512	513	493	8.01e-162	467
k141_76767_3	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	39.8	123	171	164	9.85e-27	98.2
k141_76767_3	megares|MEG_8062|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRA_1	38.2	136	171	195	2.34e-25	95.5
k141_76767_3	SARG|gb|WP_000949574.1|ARO:3005348|DfrA36	38.2	136	171	195	2.34e-25	95.5
k141_76767_3	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	34.9	129	171	167	9.32e-25	93.2
k141_76767_3	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	37.7	130	171	166	2.20e-22	87.0
k141_76767_3	SARG|CAE53424	36.9	130	171	169	6.58e-22	85.9
k141_76767_3	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	38.3	107	171	164	6.40e-21	83.2
k141_76767_3	SARG|gb|ASF80997.1|ARO:3005164|dfrA35	37.3	126	171	170	1.04e-20	82.8
k141_76767_3	SARG|gb|WP_149100971.1|ARO:3005351|DfrA39	31.3	160	171	165	3.92e-19	78.6
k141_76767_3	SARG|gi|771651285|ref|WP_045232968.1|	32.3	161	171	165	3.92e-19	78.6
k141_30030_5	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.6	341	607	582	3.01e-45	168
k141_30030_5	SARG|gi|664556405|ref|WP_031071225.1|	33.4	308	607	602	6.74e-42	159
k141_30030_5	SARG|gi|953808775|ref|WP_058042812.1|	38.1	247	607	608	1.82e-41	157
k141_30030_5	SARG|gi|817122037|ref|WP_046494699.1|	33.7	323	607	613	1.03e-39	152
k141_30030_5	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	35.8	215	607	528	5.91e-28	117
k141_30030_6	SARG|gi|493394434|ref|WP_006350564.1|	32.7	318	451	602	4.26e-45	164
k141_30030_6	SARG|gi|944009777|ref|WP_055601444.1|	32.9	328	451	628	4.87e-43	159
k141_30030_6	SARG|gi|748767925|ref|WP_040019608.1|	31.8	324	451	623	6.36e-43	159
k141_30030_6	SARG|gi|655413091|ref|WP_028811890.1|	32.6	316	451	603	9.71e-43	158
k141_30030_6	SARG|gi|516574297|ref|WP_017949361.1|	32.4	309	451	620	2.19e-42	157
k141_30030_6	SARG|gi|655401130|ref|WP_028800283.1|	32.5	329	451	599	2.41e-42	157
k141_30030_6	SARG|gi|739906046|ref|WP_037756452.1|	32.4	309	451	620	4.11e-42	156
k141_30030_6	SARG|gi|695842130|ref|WP_032755430.1|	32.1	324	451	603	2.31e-41	154
k141_30030_6	SARG|gi|663350985|ref|WP_030349761.1|	32.3	325	451	613	3.49e-41	154
k141_30030_6	SARG|gi|505420018|ref|WP_015607120.1|	31.8	324	451	603	5.95e-41	153
k141_78042_1	SARG|gi|504542119|ref|WP_014729221.1|	36.1	313	781	647	6.53e-50	185
k141_78042_1	SARG|gi|696420214|ref|WP_032990021.1|	36.1	313	781	647	8.88e-50	184
k141_78042_1	SARG|gi|851922185|ref|WP_048218206.1|	36.0	314	781	648	9.00e-50	184
k141_78042_1	SARG|gi|696375069|ref|WP_032949617.1|	36.0	314	781	648	9.00e-50	184
k141_78042_1	SARG|gi|489127020|ref|WP_003036815.1|	36.0	314	781	648	9.00e-50	184
k141_78042_1	SARG|gi|938460528|ref|WP_054624864.1|	36.1	313	781	647	1.21e-49	184
k141_78042_1	SARG|gi|1020141879|ref|WP_063264839.1|	36.1	313	781	647	1.21e-49	184
k141_78042_1	SARG|gi|490522515|ref|WP_004387938.1|	36.1	313	781	647	1.21e-49	184
k141_78042_1	SARG|gi|639225329|ref|WP_024561799.1|	35.0	314	781	648	1.22e-49	184
k141_78042_1	SARG|gi|639218559|ref|WP_024556062.1|	35.0	314	781	648	1.22e-49	184
k141_71448_3	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	519	544	655	1.02e-69	235
k141_71448_3	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	519	544	655	1.42e-69	234
k141_71448_3	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	519	544	655	1.42e-69	234
k141_71448_3	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	519	544	655	1.42e-69	234
k141_71448_3	SARG|gb|AKA86814|ARO:3003746|optrA	30.6	519	544	655	1.42e-69	234
k141_71448_3	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	519	544	655	3.84e-69	233
k141_71448_3	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	519	544	655	3.84e-69	233
k141_71448_3	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	519	544	655	3.84e-69	233
k141_71448_3	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	519	544	655	3.84e-69	233
k141_71448_3	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	519	544	655	5.35e-69	233
k141_30045_7	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.4	204	444	307	8.91e-17	79.7
k141_30045_7	SARG|gi|779838942|ref|WP_045343641.1|	28.0	200	444	648	3.87e-16	79.7
k141_30045_7	SARG|gi|817602846|ref|WP_046596462.1|	27.0	200	444	648	3.87e-16	79.7
k141_30045_7	SARG|gi|959866458|ref|WP_058145168.1|	27.5	200	444	648	3.87e-16	79.7
k141_30045_7	SARG|gi|810369244|ref|WP_046334012.1|	27.5	200	444	647	5.13e-16	79.3
k141_30045_7	SARG|gi|555246906|ref|WP_023230855.1|	27.5	200	444	648	5.14e-16	79.3
k141_30045_7	SARG|gi|950834222|ref|WP_057524365.1|	27.5	200	444	648	5.14e-16	79.3
k141_30045_7	SARG|YP_002044935	27.5	200	444	648	5.14e-16	79.3
k141_30045_7	SARG|gi|487407385|ref|WP_001675419.1|	27.5	200	444	648	5.14e-16	79.3
k141_30045_7	SARG|gi|835666879|ref|WP_047606339.1|	27.5	200	444	648	5.14e-16	79.3
k141_68138_2	SARG|YP_002861121	38.3	81	207	212	1.87e-13	65.5
k141_68138_2	SARG|YP_001779894	37.0	81	207	212	1.80e-12	62.8
k141_68138_2	SARG|YP_001389621	37.0	81	207	212	1.80e-12	62.8
k141_68138_2	SARG|YP_001785579	35.0	80	207	212	2.35e-11	59.7
k141_68138_2	SARG|U19459.gene.p01	30.9	81	207	212	7.78e-10	55.5
k141_68138_2	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	26.5	136	207	210	1.43e-09	54.7
k141_68138_2	SARG|M58472.1.gene1.p01	29.2	113	207	209	1.94e-09	54.3
k141_68138_2	NCBI|WP_021018581.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	26.7	135	207	210	2.69e-09	53.9
k141_68138_2	NCBI|WP_071846375.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	29.1	117	207	210	2.69e-09	53.9
k141_68138_2	SARG|ABF20240	29.1	117	207	210	9.44e-09	52.4
k141_52583_2	SARG|gi|446048013|ref|WP_000125868.1|	25.1	243	503	648	5.60e-16	79.7
k141_52583_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	24.9	185	503	362	9.22e-11	62.4
k141_52583_2	SARG|gi|488306124|ref|WP_002376519.1|	24.4	209	503	498	3.98e-09	57.8
k141_52583_2	SARG|gb|WP_096809342.1|ARO:3007029|salE	26.1	188	503	543	9.79e-09	56.6
k141_52583_2	SARG|AXF35727.1	24.2	211	503	497	1.99e-07	52.4
k141_52583_2	SARG|gb|AVI44920.1|ARO:3004470|poxtA	26.5	147	503	542	3.37e-06	48.5
k141_52583_2	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	26.5	147	503	544	3.38e-06	48.5
k141_52583_2	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	22.2	221	503	550	3.39e-06	48.5
k141_52583_2	SARG|gi|488231473|ref|WP_002302681.1|	22.8	215	503	492	4.23e-06	48.1
k141_52583_2	SARG|gi|488216250|ref|WP_002287458.1|	22.8	215	503	492	4.23e-06	48.1
k141_34088_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	40.4	270	295	582	3.16e-48	168
k141_34088_1	SARG|gi|951183771|ref|WP_057661487.1|	38.9	270	295	603	2.13e-47	166
k141_34088_1	SARG|gi|664170108|ref|WP_030704355.1|	38.5	270	295	603	2.13e-47	166
k141_34088_1	SARG|gi|490068471|ref|WP_003970646.1|	38.5	270	295	603	2.13e-47	166
k141_34088_1	SARG|gi|827013130|ref|WP_047175495.1|	38.9	270	295	603	4.10e-47	165
k141_34088_1	SARG|gi|517787730|ref|WP_018957938.1|	38.5	270	295	610	4.46e-47	165
k141_34088_1	SARG|gi|764446018|ref|WP_044369325.1|	38.1	270	295	605	5.82e-47	165
k141_34088_1	SARG|gi|695891735|ref|WP_032792824.1|	38.5	270	295	603	7.88e-47	164
k141_34088_1	SARG|gi|664085850|ref|WP_030624018.1|	38.5	278	295	605	8.07e-47	164
k141_34088_1	SARG|gi|662129758|ref|WP_030081404.1|	38.5	278	295	605	8.07e-47	164
k141_34088_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.7	508	578	582	2.07e-58	204
k141_34088_4	SARG|gi|505420018|ref|WP_015607120.1|	30.2	562	578	603	1.82e-53	191
k141_34088_4	SARG|gi|695842130|ref|WP_032755430.1|	30.2	562	578	603	3.46e-53	190
k141_34088_4	SARG|gi|558888514|ref|WP_023543283.1|	31.2	500	578	615	2.85e-52	187
k141_34088_4	SARG|gi|926376632|ref|WP_053705806.1|	36.9	309	578	620	5.82e-52	187
k141_34088_4	SARG|gi|943896259|ref|WP_055534530.1|	36.6	309	578	601	8.31e-52	186
k141_34088_4	SARG|gi|799286378|ref|WP_045936958.1|	36.9	309	578	620	1.10e-51	186
k141_34088_4	SARG|gi|917127754|ref|WP_051734466.1|	36.9	309	578	620	1.10e-51	186
k141_34088_4	SARG|gi|926294973|ref|WP_053631154.1|	36.9	309	578	620	1.10e-51	186
k141_34088_4	SARG|gi|772774655|ref|WP_045322518.1|	36.6	309	578	620	1.10e-51	186
k141_26722_5	SARG|gb|APB03219.1|ARO:3003986|TaeA	41.0	173	134	648	7.23e-36	128
k141_26722_5	ResF|poxtA-Ef_1_WP094899500.1_1	32.5	120	134	538	5.94e-14	66.2
k141_26722_5	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	32.5	120	134	543	5.94e-14	66.2
k141_26722_5	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	32.5	120	134	543	5.94e-14	66.2
k141_26722_5	SARG|gi|488231473|ref|WP_002302681.1|	34.1	129	134	492	2.75e-13	64.3
k141_26722_5	SARG|gi|488216250|ref|WP_002287458.1|	34.1	129	134	492	2.75e-13	64.3
k141_26722_5	SARG|gi|488247627|ref|WP_002318835.1|	34.1	129	134	492	2.75e-13	64.3
k141_26722_5	SARG|AY004350.gene.p01	34.1	129	134	492	2.75e-13	64.3
k141_26722_5	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	27.9	129	134	494	2.75e-13	64.3
k141_26722_5	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	33.8	136	134	568	5.23e-13	63.5
k141_69820_4	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.1	453	460	481	2.20e-89	279
k141_69820_4	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	36.9	452	460	451	2.53e-86	270
k141_69820_4	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	36.3	457	460	451	8.60e-84	264
k141_81683_5	SARG|gi|943909899|ref|WP_055545300.1|	26.3	551	597	601	3.60e-43	162
k141_81683_5	SARG|gi|926351744|ref|WP_053683383.1|	26.7	551	597	648	5.98e-43	162
k141_81683_5	SARG|gi|917203192|ref|WP_051809904.1|	27.2	552	597	620	2.86e-42	160
k141_81683_5	SARG|gi|917229923|ref|WP_051836635.1|	27.6	550	597	620	9.80e-42	158
k141_81683_5	SARG|gi|772774655|ref|WP_045322518.1|	27.6	550	597	620	9.80e-42	158
k141_81683_5	SARG|gi|817122037|ref|WP_046494699.1|	27.0	560	597	613	1.24e-41	158
k141_81683_5	SARG|gi|1033217078|gb|OAR27197.1|	26.7	550	597	601	1.48e-41	157
k141_81683_5	SARG|gi|799286378|ref|WP_045936958.1|	27.9	552	597	620	2.47e-41	157
k141_81683_5	SARG|gi|926294973|ref|WP_053631154.1|	27.9	552	597	620	2.47e-41	157
k141_81683_5	SARG|gi|928900436|ref|WP_053931243.1|	27.3	557	597	600	2.71e-41	157
k141_81683_20	SARG|DQ018711.1.gene4.p01	34.0	150	152	322	1.96e-21	87.0
k141_81683_20	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	35.3	153	152	314	6.65e-21	85.5
k141_81683_20	SARG|gi|738848198|ref|WP_036737307.1|	33.3	150	152	323	2.72e-20	84.0
k141_81683_20	SARG|gi|737310392|ref|WP_035293250.1|	33.3	150	152	323	2.72e-20	84.0
k141_81683_20	SARG|gi|740152780|ref|WP_037997109.1|	31.3	150	152	322	7.04e-19	80.1
k141_81683_20	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	32.0	150	152	323	9.83e-19	79.7
k141_81683_20	SARG|gi|552942232|ref|WP_023043160.1|	31.3	150	152	323	3.60e-18	78.2
k141_81683_20	SARG|AY082011.1.gene6.p01	30.7	150	152	323	2.50e-17	75.9
k141_20148_2	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.9	691	743	1024	1.07e-54	202
k141_20148_2	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.9	691	743	1024	1.07e-54	202
k141_20148_2	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.9	691	743	1024	3.51e-54	201
k141_20148_2	SARG|gb|CAA53189|ARO:3000521|mupA	24.9	691	743	1024	3.51e-54	201
k141_21874_6	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.9	264	294	354	6.43e-24	98.6
k141_21874_6	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.1	292	294	354	2.32e-23	97.1
k141_21874_6	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.8	228	294	352	5.90e-23	95.9
k141_21874_6	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	28.6	252	294	380	2.07e-22	94.7
k141_21874_6	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.6	252	294	380	2.07e-22	94.7
k141_21874_6	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.4	228	294	376	1.32e-21	92.4
k141_21874_6	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	29.4	228	294	376	1.32e-21	92.4
k141_21874_6	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	31.1	283	294	370	2.34e-21	91.7
k141_21874_6	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.5	222	294	364	3.99e-18	82.4
k141_21874_6	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.5	222	294	364	3.99e-18	82.4
k141_21874_8	SARG|gi|507023808|ref|WP_016095885.1|	41.6	305	305	309	3.88e-72	224
k141_21874_8	SARG|gi|488120365|ref|WP_002191762.1|	41.3	305	305	309	5.48e-72	223
k141_21874_8	SARG|gi|447057510|ref|WP_001134766.1|	41.3	305	305	309	1.55e-71	222
k141_21874_8	SARG|gi|488068784|ref|WP_002140181.1|	41.0	305	305	309	2.19e-71	222
k141_21874_8	SARG|gi|500448961|gb|EOP61695.1|	41.0	305	305	306	4.00e-71	221
k141_21874_8	SARG|gi|445996729|ref|WP_000074584.1|	42.0	307	305	309	4.38e-71	221
k141_21874_8	SARG|gi|507050365|ref|WP_016121371.1|	40.7	305	305	309	4.38e-71	221
k141_21874_8	SARG|gi|895808656|emb|COR83787.1|	42.0	307	305	309	4.38e-71	221
k141_21874_8	SARG|gi|446026113|ref|WP_000103968.1|	40.3	305	305	306	5.65e-71	221
k141_21874_8	SARG|gi|488067981|ref|WP_002139378.1|	41.0	305	305	309	6.18e-71	221
k141_21874_9	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.0	226	228	230	1.81e-37	129
k141_21874_9	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.5	220	228	228	2.43e-37	129
k141_21874_9	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	224	228	231	2.05e-36	127
k141_21874_9	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.8	227	228	229	2.75e-36	126
k141_21874_9	CARD|gb|ADM92605.1|ARO:3000553|adeR	34.1	226	228	247	9.38e-35	123
k141_21874_9	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.2	219	228	219	2.83e-33	118
k141_21874_9	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.4	229	228	232	1.09e-32	117
k141_21874_9	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.4	229	228	232	8.43e-32	115
k141_21874_9	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.0	229	228	232	1.18e-31	114
k141_21874_9	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.0	229	228	232	1.18e-31	114
k141_52782_1	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	48.8	215	213	239	1.84e-71	216
k141_52782_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	46.7	212	213	232	4.20e-71	215
k141_52782_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	46.7	212	213	232	4.20e-71	215
k141_52782_1	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	47.4	215	213	235	3.75e-70	213
k141_52782_1	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	47.9	213	213	233	2.85e-69	210
k141_52782_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	45.9	207	213	232	3.92e-69	210
k141_52782_1	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	47.6	212	213	231	4.36e-68	207
k141_52782_1	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	47.6	212	213	231	4.36e-68	207
k141_52782_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	47.1	208	213	231	1.24e-67	206
k141_52782_1	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	46.0	211	213	231	8.14e-66	201
k141_52782_2	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	30.0	253	842	370	2.51e-28	116
k141_52782_2	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.0	283	842	365	1.03e-27	114
k141_52782_2	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.2	218	842	381	3.27e-27	113
k141_52782_2	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.2	218	842	381	3.27e-27	113
k141_52782_2	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.5	219	842	381	4.41e-27	113
k141_52782_2	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.5	219	842	381	4.41e-27	113
k141_52782_2	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	218	842	381	8.00e-27	112
k141_52782_2	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	218	842	381	8.00e-27	112
k141_52782_2	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	31.2	218	842	380	1.06e-26	112
k141_52782_2	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.2	218	842	380	1.06e-26	112
k141_30488_4	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	39.3	522	509	533	2.95e-95	298
k141_30488_4	SARG|AF353562.gene.p01	35.2	372	509	369	1.06e-52	181
k141_30488_5	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	28.8	566	591	574	2.74e-74	246
k141_30488_5	SARG|gb|WP_104671188.1|ARO:3003948|efrA	30.7	540	591	575	2.32e-69	233
k141_30488_5	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.0	493	591	582	2.84e-65	223
k141_30488_5	SARG|gb|AAK76137.1|ARO:3000024|patA	30.9	501	591	564	1.99e-62	214
k141_30488_5	SARG|gi|1045390184|ref|WP_065479071.1|	28.1	487	591	605	3.08e-60	209
k141_30488_5	SARG|gi|662129758|ref|WP_030081404.1|	28.1	487	591	605	1.57e-59	207
k141_30488_5	SARG|gi|695865802|ref|WP_032778631.1|	28.1	487	591	605	3.01e-59	207
k141_30488_5	SARG|gi|764446018|ref|WP_044369325.1|	27.9	487	591	605	8.00e-59	206
k141_30488_5	SARG|gi|928900436|ref|WP_053931243.1|	28.2	489	591	600	1.40e-58	205
k141_30488_5	SARG|gi|664579989|ref|WP_031094015.1|	28.2	489	591	601	1.43e-58	205
k141_30488_6	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.1	582	633	579	4.59e-93	297
k141_30488_6	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.3	585	633	579	7.79e-90	289
k141_30488_6	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	32.8	516	633	578	8.33e-82	268
k141_30488_6	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.3	498	633	575	5.57e-72	241
k141_30488_6	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.7	588	633	582	1.83e-68	232
k141_30488_6	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.6	490	633	664	6.47e-66	227
k141_30488_6	SARG|gb|AAK76136.1|ARO:3000025|patB	35.9	384	633	588	1.50e-65	224
k141_30488_6	SARG|gi|860594225|ref|WP_048475168.1|	27.2	574	633	620	1.04e-64	223
k141_30488_6	SARG|gb|AAK76137.1|ARO:3000024|patA	28.3	548	633	564	2.43e-64	221
k141_30488_6	SARG|gi|926351744|ref|WP_053683383.1|	27.2	574	633	648	4.64e-64	222
k141_20341_5	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.8	247	352	355	4.51e-18	83.2
k141_20341_5	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	30.8	247	352	355	4.51e-18	83.2
k141_20341_5	SARG|ACM47285	30.8	247	352	363	4.82e-18	83.2
k141_20341_5	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.4	227	352	356	1.65e-13	69.7
k141_20341_5	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.4	227	352	356	1.65e-13	69.7
k141_20368_4	SARG|HE999704.1.gene3064.p01	31.6	215	443	241	8.59e-19	84.3
k141_20368_4	SARG|gi|441475675|emb|CCQ25429.1|	34.4	160	443	211	7.79e-14	69.3
k141_9899_5	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	27.5	193	236	494	1.46e-14	71.2
k141_9899_5	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	24.0	225	236	307	5.07e-14	68.9
k141_9899_5	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	6.63e-12	63.5
k141_9899_5	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	28.0	218	236	574	8.57e-12	63.2
k141_9899_5	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_9899_5	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_9899_5	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_9899_5	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_9899_5	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_9899_5	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_9899_7	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	35.2	576	595	579	8.12e-103	322
k141_9899_7	SARG|gb|AAK76136.1|ARO:3000025|patB	34.4	590	595	588	7.29e-99	311
k141_9899_7	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	34.8	587	595	579	6.21e-98	309
k141_9899_7	SARG|gi|664556405|ref|WP_031071225.1|	34.6	583	595	602	1.01e-94	301
k141_9899_7	SARG|gi|695842130|ref|WP_032755430.1|	34.5	592	595	603	4.32e-93	297
k141_9899_7	SARG|gi|505420018|ref|WP_015607120.1|	34.5	592	595	603	4.32e-93	297
k141_9899_7	SARG|gi|928900436|ref|WP_053931243.1|	33.6	577	595	600	2.18e-92	295
k141_9899_7	SARG|gi|664579989|ref|WP_031094015.1|	33.6	577	595	601	2.23e-92	295
k141_9899_7	SARG|gi|558888514|ref|WP_023543283.1|	33.0	576	595	615	4.46e-92	295
k141_9899_7	SARG|gi|921231571|ref|WP_053176464.1|	33.5	573	595	620	5.05e-92	295
k141_9899_8	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.1	502	588	582	1.33e-78	258
k141_9899_8	SARG|gi|648667297|ref|WP_026359044.1|	31.0	542	588	605	2.36e-77	255
k141_9899_8	SARG|gi|695842130|ref|WP_032755430.1|	30.7	550	588	603	4.56e-76	252
k141_9899_8	SARG|gi|664579989|ref|WP_031094015.1|	30.2	559	588	601	1.19e-75	251
k141_9899_8	SARG|gi|664317010|ref|WP_030845774.1|	30.1	542	588	605	1.81e-75	250
k141_9899_8	SARG|gi|663286402|ref|WP_030292859.1|	30.1	542	588	605	1.81e-75	250
k141_9899_8	SARG|gi|663342223|ref|WP_030341347.1|	30.1	542	588	605	1.81e-75	250
k141_9899_8	SARG|gi|759527374|ref|WP_043247487.1|	30.1	542	588	605	1.81e-75	250
k141_9899_8	SARG|gi|928900436|ref|WP_053931243.1|	30.3	542	588	600	2.27e-75	250
k141_9899_8	SARG|gi|663155409|ref|WP_030194633.1|	30.1	542	588	605	2.53e-75	250
k141_16958_1	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	46.6	163	155	703	3.37e-38	136
k141_16958_6	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	25.6	195	257	505	4.04e-10	58.5
k141_16958_6	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	27.2	191	257	504	5.42e-10	58.2
k141_15232_5	SARG|gi|488374619|ref|WP_002444004.1|	20.2	446	459	452	8.52e-19	87.4
k141_78460_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.8	497	507	575	7.32e-84	269
k141_78460_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	34.3	507	507	582	2.40e-83	268
k141_78460_1	SARG|gi|493394434|ref|WP_006350564.1|	29.6	497	507	602	2.72e-70	234
k141_78460_1	SARG|gi|1045390184|ref|WP_065479071.1|	30.3	498	507	605	1.53e-69	232
k141_78460_1	SARG|gi|517381192|ref|WP_018555350.1|	29.6	500	507	602	2.01e-69	232
k141_78460_1	SARG|gi|695865802|ref|WP_032778631.1|	29.4	497	507	605	2.14e-69	232
k141_78460_1	SARG|gi|558888514|ref|WP_023543283.1|	30.0	497	507	615	2.62e-69	232
k141_78460_1	SARG|gi|497748188|ref|WP_010062372.1|	29.4	497	507	605	2.99e-69	231
k141_78460_1	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	30.8	477	507	574	3.05e-69	231
k141_78460_1	SARG|gi|664180077|ref|WP_030714054.1|	29.4	497	507	605	4.17e-69	231
k141_30637_2	SARG|gb|NP_388442.1|ARO:3004476|vmlR	52.9	68	175	547	2.63e-17	77.4
k141_30637_2	SARG|GQ205627.2.gene1.p01	45.2	73	175	525	2.62e-15	71.6
k141_30637_2	SARG|gb|AGN74946|ARO:3003749|salA	47.8	67	175	541	4.19e-14	68.2
k141_30637_2	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	37.1	105	175	487	5.52e-14	67.8
k141_30637_2	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	37.1	105	175	487	7.51e-14	67.4
k141_30637_2	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	48.5	66	175	655	8.07e-14	67.4
k141_30637_2	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	48.5	66	175	655	8.07e-14	67.4
k141_30637_2	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	48.5	66	175	655	8.07e-14	67.4
k141_30637_2	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	48.5	66	175	655	8.07e-14	67.4
k141_30637_2	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	48.5	66	175	655	8.07e-14	67.4
